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 ABSTRACT 
 
The lower efficiency of the current common ways of delivering drugs to humans like oral 
administration and injection make it necessary to find more efficient delivery systems. In this 
regard, a class of nanostructured materials called mesoporous silicates such as MCM-41, 
SBA-15 has attracted the attention of many scientists as drug delivery vehicles for their 
outstanding features like high surface area, high porosity, well-ordered, tunable nanometer 
pores and “non-cytotoxic” properties.  
In this dissertation, comparative investigations of the adsorption capacity and drug release 
properties of these materials whose surfaces were functionalized with judiciously chosen 
organic groups via either post-grafting or co-condensation synthesis were conducted. 
Furthermore, two model drugs of different hydrophobicity and hydrophilicity were used in 
the study. The hydrophobicity of the ordered mesoporous silica can also be altered by 
modification of the surface with organic groups and thus, the hydrophobic interaction with 
the drug molecules can be improved. Here a comparative study between the two material 
synthesis method, the use of different functional groups and the two model drug molecules, 
Rhodamine 6G and ibuprofen, were performed. The results indicated that functional groups 
really make an obvious difference on the adsorption capacity and release profile depending 
on the type of functional group and drug molecules.  Furthermore, differences in adsorption 
capacity and drug release properties between the materials synthesized via co-condensation 
and those synthesized via post-grafting were also observed. The results of the study may give 
further insight into rational synthetic approaches to functionalized mesoporous materials with 
improved adsorption capacity and release properties for a variety of hydrophobic and 
hydrophilic drugs. In addition, pH responsive release study was conducted.  Ibuprofen and 
R6G were used as model drug molecules. For the ibuprofen loading, amine functionalized 
MCM (NH2-MCM) was chosen as carrier while amine and thiol bi-functionalized MCM 
 (NH2-MCM-SH) was chosen as carrier for the adsorption R6G. Poly (acrylic acid) PAA was 
encapsulated onto the silica matrix as pH stimuli because it is a well-know bioadhesive 
hydrogel and often used in drug formulation. 
   Among mesoporous materials, SBA-15 has large surface area, large pore size, and thick 
walls.  It possesses a hexagonal array of mesopores 6.0-20 nm in diameter, which is much 
larger than the 3.0-nm pores characteristic of the MCM-41 and MCM-48. Their wall 
thickness is an important parameter for providing a high degree of hydrothermal stability and 
improved mechanical stability compared to mesoporous MCM-41 and related silicas, and 
thus a sufficiently long lifetime in biological environments. Therefore, SBA-15 mesoporous 
materials could be modified with various surface functional groups and still preserve the 
large pore channels and surface areas for drug adsorption and desorption after modification.  
So, drug adsorption and release study over SBA-15 and comparative study between SBA-15 
and MCM-41 was also investigated.  Results show that SBA-15 has larger release amount 
than MCM-41.  
In this dissertation, the oxidation of epinephrine in the presence of SBA-15 and MCM-41 
particles was also carried out. Dense silica particle was test as a control. It was reported that 
caffeine (1,3,7-trimethylxanthine) can work as a scavenger of the hydroxyl radical at 
millimolar concentrations. Here we investigated the epinephrine oxidation in the presence of 
caffeine. Antioxidant effects of caffeine and its metabolites were also evaluated by the 
epinephrine oxidation rate. Same experiment was also performed with its isomer, isocaffeine. 
It was found that influence of mesoporous silica (MCM-41 and SBA-15) nanoparticles and 
dense silica nanoparticles on epinephrine oxidation is pH-dependent. Aslo, in the presence of 
either caffeine or isocaffeine, the oxidation rate of epinephrine by MSN will be slowed down 
and with the increase of caffeine or isocaffeine concentration, the oxidation rate decrease 
accordingly. 
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CHAPTER 1 INTRODUCTION  
  
1. 1 Background 
 
Nanoparticles presence in commercial products has been more and more common these days. 
According to the ASTM standard definition, nanoparticles refer to particles with a lengths 
ranging from 1 to 100 nanometers in two or three dimensions.
1
 It is predicted that production of 
nanoparticles will increase from the about 2300 tons to 58000 tons by 2020.
2
 Nanoparticles have 
been attracting great interest of many scientists because they act as a bridge connecting bulk 
materials and atomic or molecular structures. While bulk materials have constant physical 
properties no matter what the sizes they have, it is very different when it comes to nanomaterials. 
Size-dependent properties like quantum confinement in semiconductor particles are observed. 
When the size of the materials is decreased to the nanoscale, the materials can show very 
different properties compared to the properties they have on a macroscale and thus result in 
many unique applications. For instance, opaque substances such as copper become transparent; 
inert materials such as platinum attain catalytic properties; stable materials such as aluminum 
turn combustible;  solids like gold turn into liquids at room temperature  and insulators like 
silicon become conductors when it come to nanoscale. 
3
 
Among these nanoparticle materials, nanoporous material is one of the most studied fields, 
expecially mesoporous materials. Generally, nanoporous materials can be divided into three 
categories based on their size according to IUPAC notation: 
4
 (1) microporous materials, (2) 
mesoporous materials, (3) macroporous materials  
Microporous materials have pore diameters of less than 2 nm, mesoporous materials have 
pore diameters between 2 nm and 50 nm and macroporous materials have pore diameters of 
2 
 
greater than 50 nm. One example of microporous materials is Zeolites which are aluminosilicate 
minerals commonly used as commercial adsorbents.  Zeolites are widely used in industry for 
water purification, as catalysts, and in nuclear reprocessing. Their biggest use is in the 
production of laundry detergents. They are also used in medicine and in agriculture. But one 
drawback of this kind of materials is its small size especially in the applications involved in guest 
and host molecule interaction. For example in catalyst application, their small size limits the 
transportation of molecule while fast mass transfer of the reactants and products to and from the 
active sites is required for catalysts. Also it doesn’t work when it comes to bigger molecules and 
reactants which sizes are too big to go into and come out of the small pores. Same situation 
happens in the drug delivery application for big drug molecules.  
The main research work in this thesis is drug delivery and mesoporous materials were used in 
all the studies. 
1. 2 Mesoporsous silica materials 
 
The zeolite has small pore size of about 1.5nm and was therefore limited in its application 
while mesoporsous materials have larger pore sizes than zeolite molecular sieves. Besides their 
larger sizes, the mesoporous materials also have very large specific surface areas, ordered pore 
systems, and well-defined pore radius distributions like zeolites. Compared to the dimensions of 
the zeolite micropores (<2nm), mesopores (2-50 nm) make faster migration of guest molecules a 
reality in the host frameworks. The first mesoporous material of a long range order was first 
reported in 1990 by T. Yanagisawa et al.
5  
Later, it was also developed by the group of the former 
Mobil Oil Company in 1991.
6,7 
 Since then, the development of porous materials with large 
specific surface areas is currently an area of extensive research, particularly with regard to 
potential applications in areas such as adsorption, chromatography, catalysis, sensor technology, 
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gas storage, drug delivery, gas sensing, optics, and photovoltaics. The most studied M41S 
mateirals include the silica solids MCM-41 (with a hexagonal arrangement of the mesopores), 
MCM-48 (with a cubic arrangement of the mesopores), and MCM-50 (with a laminar 
structure).
6-9
 Among these MCM materials, MCM-41 is chosen and investigated in this thesis. 
Besides MCM materials, another most commonly used mesoporous silicas have been SBA-type 
(Santa Barbara Amorphous) mesoporous materials. SBA materials were first synthesized in 
Galen Stucky’s group at the University of California at Santa Barbara.10 SBA-type mesoporous 
materials cab be synthesized in the presence of triblock poly(ethylene oxide)-poly(propylene 
oxide)-poly(ethylene oxide) (PEO-PPO-PEO) copolymers, such as EO20PO70EO20 (Pluronic 
P123). A series of ordered SBA-type mesoporous silica mateirals with different d spacings and 
pore sizes was prepared by using poly (alkylene oxide) triblock copolymers with different EO to 
PO ratios. Among these SBA materials, SBA-15 is one of the most investigated one from SBA 
family with hexagonal mesoporous silica structure. Upon removal of the pluronics templates, a 
highly ordered mesoporous SBA-15 with large pores and thicker silica wall can be obtained.
 
It 
has BET surface areas of 690-1040 m
2
/g, large pore sizes of 46-300 Å, and unusually large pore 
volumes up to 2.5 cm
3
/g, with silica wall thicknesses ranging from 31 to 64 Å.
10, 11
 SBA-15 
mesoporous materials could be modified with various surface functional groups and still preserve 
the large pore channels and surface areas for drug adsorption and desorption.
12-15
 The pH of the 
solution is an important factor for the successful arrangement and assembly of the alkyl 
ammonium or the tri-block copolymer templates. Besides, the diameter of SBA is much larger 
than the pore size of the MCM-41 and MCM-48, there is also difference from M41S type 
materials in the preparation process. The pH value of the medium at which M41S and SBA-type 
4 
 
materials are synthesized is also completely different. SBA-type materials are synthesized under 
acidic solution (pH 2.0) while M41S ones are conducted in basic solutions, i.e. at a pH above 12.   
The large pore size, high surface area and large pore volume make the mesoporous materials 
suitable as a potential carrier for various chemical compounds such as molecules with biological 
activity. However, in order to achieve an effective control of adsorption and release of the guest 
molecules, it would be necessary to modify the chemical nature of the wall of mesoporous pore 
with specific functional group base on the hyrdrophobicity and hydrophilicity of adsorbed 
molecules. In this context, the presence of a high concentration of silanol groups on the surface 
inside and outside the pore can be functionalized to control pore size and surface properties, and 
thus the drug delivery kinetics would be affected by the interactions between the drug and matrix. 
MCM-41, MCM-48, and SBA-15 silica materials have been functionalized with, for example, 
amino,
16-28
 diamino,
28-30
 triamino,
28, 30
 ethylenediamine,
31,32
 malonamide,
33
carboxy,
21, 26
 
Carboxylic Groups 
34, 35
 thiol,
19, 25, 29, 36
sulfonic acid groups, 
36
 dithiocarbamate,
37
 and imidazole 
groups,
38-41
alkyl,
42 
1-allyl,
43
 can be incorporated into the pore walls of the silica network.
 
Generally speaking, surface functionalization of mesoporous silica materials via covalent 
bonding of organic groups can be achieved by three methods:  
1) Post-grafting of the surface of extracted mesoporous silica material (grafting), 
44-46
 
2) Condensation of silica precursor (TEOS or TMOS) and organosilica precursor mixtures (co-
condensation),
 44-46
 
3) Incorporation of organic groups directly into the materials by the use of bridging organosilica 
precursors (periodic mesoporous organosilicas). 
1.2. 1 Post-synthetic method (Post-grafting) 
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 Grafting procedures are based on modification of the silica surface with organic groups 
through silylation reactions occurring on isolated (≡Si-OH) and geminal (＝Si(OH)2) silanol 
groups. Organosilanes of the (RO)3SiR type like (CH3O)3Si(CH2)3NH2, (CH3O)3Si(CH2)3SH is 
chosen  and react with the free silanol group on the surface. Different organic group can be 
functionalized on the surfaces by the changing of organic residue R. On the one hand, post-
grafting method can retain starting silica materials and results in well-ordered functionalized 
mesostructured materials, on the other hand, it often produces non-uniformly distributed organic 
groups because the organic moieties can congregate more on channel opening and on the exterior 
surfaces 
47-50
 and the further diffusion of molecules into the center of the pores can thus be 
affected.  
Generally, after surfactant forms a micellar structure, the mixture of tetraalkoxysilanes 
(TEOS or TMOS) and terminal trialkoxyorganosilanes are added to it and then hydrolyzed and 
condense on the walls of surfactant micellar template via electrostatic attraction. 
79
 Since the 
organic functionalities are directly composed into the silica matrix, the congregation of organic 
moieties at pore entrance will be not a problem via the co-condensation method. Furthermore, 
Co-condensation synthetic method of mesoporous materials involves a one-step procedure and 
allows better control of the loading and distribution of the organic groups 
80
 although it often 
produces materials with less ordered mesoporous structures. Generally speaking, low degree of 
structural integrity and long-range periodicity as well as lower surface area would be produced 
when the organosilane concentration in the synthesis exceeds ~25% 
80
. 
In addition, an increased loading of the incorporated organic moieties will result in the 
decrease of the pore diameter, pore volume, and surface areas. In order not to destroy the organic 
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functionality during removal of the surfactant, extractive methods are usually used, instead of 
calcination. 
1.2. 2  Co-Condensation  
 
Besides post-grafting method, another alternative method to synthesize organically 
functionalized mesoporous silica materials is the co-condensation method or one-pot synthesis. It 
involves a one-step co-condensation of tetraalkoxysilanes such as tetraethyl orthosilicate (TEOS) 
with organosilanes such as MPTS, VTS, and offers a higher and more uniform surface coverage 
of functional groups and thus a better control over the surface properties of the resulting 
functionalized materials. Since the pioneering work in the research groups of Stein,
74
  Mann,
75,76
 
Macquarrie
77
 and Stucky,
78
 co-condensation reactions have been used to prepare hybrid 
mesoporous silicates under a wide range of reaction conditions. A number of organically 
modified silica phases have been synthesized by co-condensation. Through the use of the 
respective organosilane, organic functionalities such as carboxylic acid group
34 
alkyl,
51,52
 
vinyl/allyl,
51,53-59
 thiol,
51,58,60,61
 aromatic groups 
52, 58, 62-66
  and amino.
58,59,67-73
 
1.2.3 Preparation of Periodic Mesoporous Organosilicas (PMOs)    
 
PMOs were first synthesized in 1999 by three different research groups. 
81-83
 Since then, a 
number PMOs were synthesized in the same way 
84-93
. They applied the same procedure for the 
synthesis of ordered pure mesoporous silica by structuring with ionic surfactants to organosilica 
hybrid  after replacing organosilica precursors with bridged organosilica precursors (RO)3Si-R-
Si(OR)3. Hydrolysis and condensation reactions of bridged organosilica precursors result in the 
materials in which the organic units are incorporated in the three-dimensional network structure 
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of the silica matrix through two covalent bonds. So, the organic units are distributed 
homogeneously in the silica matrix. It is very different from the materials obtained by grafting 
and co-condensation method.  These materials have large inner surface areas of up to 1800 m
2
/g 
as well as high thermal stability. However, the pores are completely disordered of a wider size 
distribution. Generally speaking, PMO materials have significant advantages over pure 
mesoporous silica and organic functionalized mesoporous silica synthesized by postgrafting and 
co-condensation method. They are considered as promising candidates for a number of 
applications, such as in catalysis, adsorption, chromatography, nanoelectronics and active 
compound release systems. 
1.2. 4 Application in drug delivery 
 
Drug delivery system (DDS) is a carrier which can regulate the drug delivery rate and targets 
specific areas of the body by modifying the materials with specific groups. The method by which 
a drug is delivered can have a significant effect on its therapeutic efficacy. Because with 
traditional therapy, the drug usually lose effect before it reach the desired site in the body. So, 
DDSs are designed to keep therapeutic effect during the treatment period till it reach the desired 
site.
143
 An ideal drug-delivery system need meet the following characters:     
(1) Non-toxic and biodegradable;  
(2) High loading capacity;  
(3) Ability to protect the drugs from decomposition;  
(4) Ability to seal the drug in order to prevent the drug from being released prior to reaching 
the target-site by modified pore openings with caps, and protect the body from possible side-
effects of the drug; 
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(5) Ability to direct the small carrier structure throughout the human organism to the desired 
target-site; 
 (6) The caps should open reliably in order to release the drug efficiently after reaching the 
target-site.  
Considering these demanding requirements, various drug-delivery systems (polymers, 
micelles, polymeric nanocapsules, and various nanoparticles etc.) have been studied so far. It is 
not easy to meet all the criteria for the delivery systems and the drug delivery systems mentioned 
above all have some disadvantages. For example, drug is released instantaneously or is 
decomposed before reaching the desired site in some system. The controlled drug release process 
is attractive and has been widely and intensively studied. Much of this work involves polymers 
which enable the drug to be delivered at relative constant rate by diffusion control from polymer 
or polymer composites over time. However, in the polymer delivery system, the drug is usually 
deposited via coating, wet granulation or direct compression, even by mechanical mixing both 
matrix and drug which have the disadvantage of non-uniform distribution and thus can influence 
the release rate between different drug compositions. More importantly, cell-targeting remains a 
great challenge for many classes of drug-delivery systems. Therefore, much improvement in this 
field and a smart drug delivery alternative are badly needed and other material and method 
avoiding these disadvantages was explored. Nanomaterials has been used by many researchers 
for drug delivery and the mesoporous material MCM-41 was first used as a DDS in 2001.
144
 The 
reason to choose MCM-41 as DDSs is  its non-toxic, biodegradable and biocompatible characters; 
145-148
 it has an ordered and tunable pore network of homogeneous size which allows fine control 
of the drug load and release kinetics; The high pore volume and high surface area of the MCM-
41 allows to host the required amount of pharmaceutical and implies high potential for drug 
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adsorption; porous network that can be capped; possibility to be modified with specific receptors 
on the surface. The last but not the least, it has free silanol on the surface which can be 
functionalized by desired functionalized organic group to allow better control over drug loading 
and release. The characters of mesoporous silica materials make it a perfect candidate for many 
applications, like catalysis,
94-99
 adsorbents,
100,101
 drug delivery 
102-141
 and sensor
142
 Among these 
applications, application in drug delivery is a promising research field and research presented in 
this thesis is focused on this. 
1. 3  Overview of Dissertation 
 
In Chapter 2, surfaces of mesoporous materials are functionalized with judiciously chosen 
organic groups via post-grafting or co-condensation of various organosilanes, and then 
comparative and systematic investigations of the adsorption capacity and drug release properties 
of mesoporous materials were conducted. Furthermore, two different molecules of different 
hydrophobicity and hydrophilicity were used as model drugs in the study. In Chapter 3, R6G and 
ibuprofen adsorption and release study over different functionalized SBA-15, i.e., Ex-SBA, SH-
SBA, COOH-SBA was studied, and then COOH-MCM was also studied to compare the different 
adsorption and release properties from SBA materials. In Chapter 4, influence of mesoporous 
silica (MCM-41 and SBA-15) nanoparticles and dense silica nanoparticles on epinephrine 
oxidation was investigated. Antioxidant effects of caffeine and its metabolites were also 
evaluated by the epinephrine oxidation rate. Same experiment was also investigated with its 
isomer, isocaffeine. In Chapter 5, pH responsive relase study of R6G over amine functionalized 
MCM (NH2-MCM) and ibuprofen release study over amine and thiol finctionalzied MCM (NH2-
MCM-SH) were conducted. Poly (acrylic acid) PAA was encapsulated onto the silica matrix as 
10 
 
pH stimuli and the release study was carried out at pH 1.0 and pH 7.4. Finally, the conclusion 
and future study are addressed in chapter 6. 
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CHAPTER 2 FUNCTIONALIZED MESOPOROUS MATERIALS FOR 
ADSORPTION AND RELEASE OF DRUG MOLECULES 
 
2.1 Introduction and Background  
 
At present, the most common ways of delivering drugs to humans are oral administration and 
injection. However, these methods have lower efficiency for some therapies. Some therapeutic 
agents are unstable or are poorly soluble; therefore, new delivery systems for them are required. 
Functionalized nanostructured materials are increasingly considered as great candidates to make 
drug delivery vehicles and controlled drug release systems. This is because they have suitable 
platforms that can help minimize adverse reactions and unwanted side effects, that many 
conventional drugs used today often pose. 
1,2
 With some drug administration methods, the drugs 
have to often pass through various physiological obstacles before they reach to their desired 
target, thus decreasing the amount of drug that gets to the targeted site. The inability to deliver 
controlled therapeutic concentration of drugs to the desired location can result in a decrease in 
the efficacy of the drug.
1,2
 Increasing the concentrations of drugs to be delivered by using 
nanomaterial based drug delivery vehicles with improved capacity of adsorption and controlled 
drug release properties can enhance the efficiency of the drugs.  
       Since their discovery in the early 1990’s, 3-6 a class of nanostructured materials called 
mesoporous silicates such as MCM-41 have attracted the attention of many scientists as drug 
delivery vehicles 
7-12
 because of their outstanding features such as high surface area (typically 
1000 m
2
/g), high porosity (typical pore volumes of 0.5 – 1.5 cm3/g), well-ordered, tunable 
nanometer pores (typically 2-15 nm pore diameter) 
13-19
 and “non-cytotoxic” properties. 20-23 
Figure 2.1 shows the procedure of the synthesis. 
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Figure 2. 1 Assembly of surfactant and followed by condensation of silica precursor and thus 
result in hexagonal arrangement of mesoporous material via calcination or extraction  
 
 
 In fact, different types of mesoporous silica nanomaterials were already proved to be capable 
of carrying high dosages of a variety of drugs in their mesopores. 
7-12, 24-31
 Additional benefits of 
mesoporous silica materials for drug delivery include the simplicity of tuning their pore sizes by 
changing their templates in order to better accommodate drug molecules of different sizes as 
demonstrated by extensive works by Vallet-Regí and co-workers 
32, 33
 as well as other 
researchers 
32-34
. While smaller drug molecules and biomolecules can be accommodated in 
mesoporous materials with smaller as well as bigger pore sizes, larger drug molecules require 
materials with bigger pore diameters. 
35, 36
 Furthermore, mesoporous silica materials contain 
residual silanol groups that can further be functionalized by different organic groups in order to 
modify their surface properties. 
37-39
 This creates favorable surface – drug interactions, which in 
turn result in improved adsorption capacity of the materials for drug molecules. Lin and co-
workers have shown that the organic functionalization of mesoporous materials can also 
influence their biocompatibility. 
40-43
 In addition to surface functional groups, the morphology 
and size of the mesoporous materials also have an important influence on drug release 
characteristics. 
44, 45
 
Generally, surface functionalization of mesoporous silica materials via covalent bonding of 
organic groups can be achieved by two methods: i.e., post-grafting synthesis 
46-48
 and co-
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condensation. 
46-48
 Although post-grafting method results in well-ordered functionalized 
mesostructured materials, it often produces non-uniformly distributed organic groups because the 
organic moieties can congregate more on the channel pore mouth and on the exterior surfaces. 
49-
52
 Co-condensation synthetic method of mesoporous materials involves a one-step procedure and 
allows better control of the loading and distribution of the organic groups 
53
 although it often 
produces materials with less ordered mesoporous structures. In particular, low degree of 
structural integrity and long-range periodicity as well as lower surface area would be produced 
when the organosilane concentration in the synthesis exceeds ~25%. 
53
 
Herein comparative investigations of the adsorption capacity and drug release properties of 
mesoporous materials whose surfaces are functionalized with judiciously chosen organic groups 
via post-grafting or co-condensation of various organosilanes were conducted. Furthermore, two 
different hydrophobic and hydrophilic molecules were used as model drugs in the study. The 
approach of organic functionalization of mesoporous materials for drug delivery has been 
considered previously. 
54-72
 The most studied system is ibuprofen adsorption on functionalised 
matrices. When the MCM-41 or SBA-15 surface is functionalised with amino groups, 
56, 57
 there 
is an ionic interaction between the carboxylate groups of ibuprofen and the ammonium groups on 
the matrix surface. The hydrophobicity of the ordered mesoporous silica can also be altered by 
modification of the surface with alkyl chains. 
58
 As a result, the hydrophobic interaction with 
hydrophobic drugs can be improved. For instance, erythromycin release from functionalized 
matrices was much slower compared to unmodified material. 
60
 Here a comparative study 
between grafting and co-condensation as well as the use of different functional groups and two 
different (model) drug molecules have been performed. Functional groups including 3-
aminopropyl, 3-mercaptopropyl, vinyl, and secondary amine groups were used to functionalize 
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the mesoporous materials while rhodamine 6G (Figure 2.2) and ibuprofen were used as probe 
molecules to investigate the materials’ adsorption and release properties. Our comparative study 
is intended to obtain the relative effect of functional groups as well as type of synthetic method 
to the functionalized materials on the adsorption and release properties of the materials for 
different molecules. The self-assembly of the mesoporous materials was carried out with 
cetyltrimethylammonium bromide (CTAB) surfactant producing MCM-41 type materials with 
pore diameters of ~2.7-3.3 nm and moderate to high surface areas up to ~1000 m
2
/g. By 
changing the organic groups, the properties of the mesoporous materials from hydrophobic to 
hydrophilic were tuned and their adsorption and release properties for different (model) drug 
molecules such as rhodamine 6G and ibuprofen were varied.  
Rhodamine 6G and ibuprofen were chosen as probe molecules in our study because of their 
differences in hydrophilicity (or hydrophobicity), which allows the investigation of interaction of 
different molecules with functionalized mesoporous materials. 
61-67
 Furthermore they are easy to 
probe by UV-Vis spectroscopy. The solubility of rhodamine 6G and ibuprofen is dependent on 
solvent and pH of solution. For instance, the solubility of rhodamine 6G is 20 g/L in water; 40 
g/L in butanol, 80 g/L in ethanol, 15 g/L in propanol and 100 g/L in diethylene glycol. 
Rhodamine 6G has increased solubility at when pH increases.
73
 Ibuprofen, which is a relatively 
weak acid with pka value of 4.4, has low solubility in water and at acidic pH. Ibuprofen has an 
intrinsic solubility of ~0.06 mg /mL-1
 
in water. Ibuprofen is sparingly soluble in hexane and 
freely soluble in ethanol, octanol and dimethyl sulfoxide and chloroform with values of >10 g/L 
in acetone, >10 g/L in ethanol, 33 g/L in octanol, and 3.3 g/L in hexane. The solubility of 
ibuprofen increases sharply with pH, i.e. the drug being largely insoluble at low pH, but readily 
soluble at alkaline pH. For example in water, its solubility is ~0.5 x 10
-1
 g/L
 
at pH < 2.00 but 
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~1x10
2 
g/L at pH = 7.5.
74
 Based on these properties or because rhodamine 6G is quite soluble in 
water while ibuprofen is rather soluble in solvents such as hexane and ethanol, we have 
considered rhodamine 6G to be hydrophilic probe molecule while ibuprofen to be hydrophobic 
in this study. They, therefore, are expected to show different adsorption and release properties in 
organic functionalized mesoporous materials.  
Our studies indicated that while the samples functionalized with mercaptopropyl and vinyl 
groups resulted in high adsorption capacity for rhodamine 6G, those functionalized with amine 
groups showed higher adsorption capacity for ibuprofen. Similarly, the drug release properties 
also varied from sample to sample, depending on the type of functional groups they contained. 
Furthermore, differences in adsorption capacity and drug release properties between the 
materials synthesized via co-condensation and those synthesized via post-grafting were also 
observed. The results of our study may give further insight into rational synthetic approaches to 
functionalized mesoporous materials with improved adsorption capacity and release properties 
for a variety of hydrophobic and hydrophilic drugs. 
 
Figure 2. 2 Structure of Rhodamine 6G molecule 
 
2.2 Results and Discussion 
2.2.1. Characterization of Functionalized Mesoporous Materials  
2.2.1.1 Powder X-ray Deffraction and Transmission Electron Microscopy (TEM) 
33 
 
 
 
The X-ray diffraction (XRD) patterns of the functionalized mesoporous materials and 
representative TEM images of samples synthesized by post-grafting and co-condensation are 
shown in Figure 2.3, Figure 2.4, and Figure 2.5 respectively. The X-ray diffraction (XRD) 
patterns of all the samples synthesized by postgrafting exhibited hexagonally ordered 
mesoporous structure that is characteristic of MCM-41type materials (Figure 2.3). The X-ray 
diffraction (XRD) patterns (A and C in Figure 2.4) of the samples synthesized by co-
condensation from VTS and MPTS (Co-VTS and Co-MPTS) also showed ordered 
mesostructures; however, those synthesized from APTS (Co-APTS) and BTSPA (Co-BTSPA) 
revealed less ordered mesostructures. The weakly ordered mesostructure in the latter results 
probably because hydrophilic organoamine groups in APTS and BTSPA cause some 
perturbation in the center or the hydrophobic core of the surfactant micelles during co-
condensation synthesis of mesostructured materials from these organosilanes.
75
 From the (100) 
Bragg peak, the d-spacing values of both Co-VTS and Co-MPTS samples as well as those 
synthesized by post-grafting were calculated to be ~4.3-4.5 nm. Furthemore, except for a slight 
decrease in their (100) Bragg reflection, the samples remained mesostructured with the same unit 
cell size after adsorption and release of rhodamine 6G (R6G) and ibuprofen guest molecules (B 
and D in Figure 2.4). The decrease in the intensity of Bragg reflection is probably a result of a 
slight decrease in electron contrast between the mesopores and the mesopore channel walls due 
to the confinement of the R6G and ibuprofen guest molecules inside the mesopores.
39
 Although 
the unit cells remained the same, the pore diameters and surface areas of the materials decreased 
after adsorption of the drug or guest molecules (See below).  
The morphology and mesopores of the materials are shown in Figure 2.5. Although the 
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morphology and size of the mesoporous materials are known to have an important influence on 
drug release characteristics, 
76, 77
 the materials we used for our comparative studies are made 
from the same batch of parent material, and consequently had similar morphologies. This is, 
therefore, expected to cause little difference on the adsorption and release properties of the 
materials in our studies.  
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Figure 2. 3  Powder X-ray diffraction (XRD) patterns of functinalized mesoporous samples 
synthesized by post-grafting of organosilanes (A) APTS, (B) BTSPA, (C) MPTS and (D) VTS 
onto mesoporous silica 
 
36 
 
0 2 4 6 8
0
500
1000
1500
2000
2500
0 2 4 6 8
0
500
1000
1500
2000
2500
3000
3500
(100)
2(degrees) 2(degrees)
D
C
In
te
n
s
it
y
(a
.u
.)
In
te
n
s
it
y
(a
.u
.)
A
B
(100)
 
Figure 2. 4  Powder X-ray diffraction (XRD) patterns of functionalized mesoporous samples 
synthesized by co-codensation of organosilanes (A) MPTS and (C) VTS with the corresponding 
XRD patterns of the samples after R6G adsorption shown in (B) and (D), respectively. 
 
 
 
 
Figure 2. 5  Low resolution and high resolution TEM Images of mesoporous samples 
synthesized by post-grafting (A, B) and (C, D) co-condensation. 
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2.2.1.2 Nitrogen Gas Adsorption (BET) 
 
 
The structures of the functionalized samples were also characterized by nitrogen gas 
adsorption. The gas adsorption (Figure 2.6) showed a type IV isotherm with sharp capillary 
condensation steps for all the samples synthesized by post-grafting as well as for samples Co-
MPTS and Co-VTS that were synthesized by co-condensation. This is indicative of the presence 
of mesoporous structure in these materials. This result is also consistent with their XRD patterns 
shown in Fig. 2.3 and Fig. 2.4. The specific surface area and pore sizes of the materials are 
reported in Table 2.1. It is worth noting that all the samples synthesized by post-grafting and the 
samples synthesized by co-condensation from VTS and MPTS showed high surface areas. The 
samples synthesized from APTS and BTSPA by co-condensation showed significantly lower 
surface areas.  
 
(A) 
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Figure 2. 6  Nitrogen adsorption isotherms samples synthesized via (A) post-grafting and (B) co-
condensation of different organosilanes 
 
 
The pore size distributions of the materials are shown in Figure 2.7 and their average 
mesoporous diameters are listed in Table 2.1. It is important to note here that the absolute values 
of the pore diameters have to be treated with caution as the BJH method, in general, 
underestimates the pore diameter of mesoporous materials.
78-80
 We also calculated corrected 
values of pore diameters by using the equation developed by Kruk and Jaroniec.
78, 80
 The results 
reveal that the materials synthesized by post-grafting have average mesopore diameters between 
2.7-3.2 nm while the samples synthesized by co-condensation have average mesopore diameters 
of 3.0-3.3 nm (Table 2.1). The average pore diameters of samples Co-VTS and Co-MPTS were 
slightly lower than the corresponding samples synthesized by post-grafting. This is consistent 
with previously reported materials from co-condensation of hydrophobic organosilanes, which 
showed smaller pore sizes and whose pore sizes depend on the relative concentration of the 
organonosilane in the solution.
81, 82
 Furthermore, upon immobilization of the guest or drug 
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molecules, the surface areas of the materials decreased. For instance, the surface area of the Co-
MPTS sample decreased from 885 m
2
/g to 352 m
2
/g after getting saturated with rhodamine 6G 
(see below) 
(A) 
 
(B) 
 
Figure 2. 7 Pore size distribution of functionalized samples synthesized by (A) post-grafting 
APTS, BTSPA, MPTS, and VTS, onto MCM-41 and (B) co-condensation of APTS, BTSPA, 
MPTS, and VTS with TEOS 
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Table 2. 1  Structural data of the organic functionalized mesoporous materials 
Samples  Surface Area 
(m
2
/g)  
Average BJH Mesopore 
Diameter (Å) 
a
  
Average Mesopore Diameter 
by KJS Method (Å) 
b
  
Co-APTS  189.0  2.4  3.1  
Co-BTSPA  238.1  2.3  3.2  
Co-MPTS  885.1  2.2  2.7  
Co-VTS  1183.4  2.4  3.0  
Grafting-APTS  887.3  2.0  3.0  
Grafting-BTSPA  852.5 2.0  3.0  
Grafting-MPTS  952.1 2.1  3.2  
Grafting-VTS  812.0  2.2  3.3  
a
The pore diameters were obtained by the BJH method, which is known to underestimate the 
pore diameter of mesoporous materials.
78-80
 It is, therefore, worth noting that the absolute values 
of these pore diameters have to be treated with caution. 
b
 The pore diameters were calculated by 
an equation developed by Kruk and Jaroniec.
78, 80 
 
 
2.2.1.3 Solid-state NMR spectra of various functionalized mesoporous samples 
 
 
Typical 
29
Si CP-MAS NMR spectra for the functionalized samples are shown in 
Supplementary Materials (Figure 2.13). The spectra showed peaks at around –100 and –110 ppm 
which correspond to hydroxyl containing silicon sites (Q
3
 
or SiO1.5OH) and cross-linked silicon 
(Q
4
 
or SiO2), respectively. The spectra also exhibited peaks between –50 and –80 ppm that were 
assigned to the Si atoms covalently bonded to organic groups {or T
2
 
[(SiO)2Si(OH)(CH2-)] and 
T
3
 
[(SiO)3Si(CH2)] sites}. 
68-72
 The 
13
C CP-MAS NMR spectra (Figure 2.14) of APTS and MPTS 
functionalized samples showed a signal at ~10 ppm, which was assigned to methylene, -CH2-, 
groups that are directly bonded to silicon atom. The resonances between 20-30 ppm were 
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attributed to the other methylene and the terminal methyl groups of the propyl chain. 
83
 
Furthermore, Figure 2.14, B, Figure 2.14, C, and Figure 2.14, D showed additional minor peaks 
at ~30 ppm that were assigned to carbon atoms of residual CTAB surfactant in the pores of the 
samples. These peaks were observed in the spectra for samples grafted with MPTS, VTS and 
BTSPA while they were not visible on the spectrum for the sample grafted with APTS (Figure 
2.13, A) though all these four samples were prepared from the same batch of surfactant-extracted 
MCM-41. This is because the density of organic groups grafted in the former three samples was 
significantly lower than that in the APTS-grafted sample. Thus, the residual surfactant peaks 
appeared more visible with respect to the peaks corresponding to the organic functional groups in 
the former than in the latter.  
2.2.1.4 Thermogravimetric (TGA) traces of various functionalized mesoporous materials 
 
The mesoporous materials were further characterized by thermogravimetric analysis under 
nitrogen (Table 2.6 and Figure 2.15) and elemental analysis (Table 2.2). These results further 
corroborated the results obtained from solid-state NMR. Thermogravimetric analysis of organic 
functionalized mesoporous materials under nitrogen or air were previously used by many groups 
for characterization of organic functionalized mesoporous materials.
84-87
 The TGA traces of the 
functionalized samples (Figure 2.15,) showed a weight loss below 100 °C due to physisorbed 
water 
88
 and, most importantly, a weight reduction between ~200-600°C due to the loss of 
organic functional groups. Furthermore, a slight weight reduction after 600°C due to loss of 
water molecules from condensation of residual silanols was observed. Elemental analysis 
revealed that the mmol organic/g of sample synthesized by post-grafting of APTS, BTSPA, 
MPTS, and VTS were 2.17, 0.94, 0.97, and 1.53 mmol/g, respectively (Table 2.2). This indicated 
that the surface density of functional groups that were grafted decreased in the order of APTS > 
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VTS > M TS ≈ BTS A. On the other hand, the mmol organic/g sample in the samples 
synthesized by co condensation, Co-MPTS and Co-VTS, were 2.18 and 2.57 mmol/g, 
respectively (Table 2.2). This indicates that the mmol of functional groups in the samples is 
higher for sample prepared from VTS than that from MPTS (or Co-VTS > Co-MPTS). We can 
also conclude from Table 2.2 that the sample synthesized from MPTS and VTS by co-
condensation had more functional groups compared to the corresponding sample synthesized by 
post-grafting.  
 
 
 
Table 2. 2  Density of grafted organic groups (mmol/g) of functionalized mesoporous materials 
determined from elemental analysis and adsorption capacity of the samples for rhodamine 6G.  
 
Samples  Grafting 
APTS  
Grafting 
BTSPA  
Grafting 
MPTS  
Grafting 
VTS 
a
  
Co-MPTS  Co-VTS 
a
  
mmol R6G adsorbed/g 
sample  
1 x 10
-4
  2 x 10
-4
  0.14  0.04  0.29  0.08  
mmol organic groups/g 
sample 
b
  2.17  0.94  0.97  1.53  2.18  2.57  
Average number of 
adsorbed molecules per one 
surface ligand  
4.6 x 10
-5
  2.1x 10
-4
  1.4 x 10
-1
  2.6 x 10
-2
  1.3 x 10
-2
  3.1 x 10
-4
  
Normalized with Surface 
Area (mmol R6G 
adsorbed/Surface area, 
mmol/m
2
)  
1.1 x 10
-7
  2.3 x 10
-7
  1.5 x 10
-4
  4.9 x 10
-5
  3.3 x 10
-4
  6.8 x 10
-5
  
a
 mmol/g the samples functionalized with VTS could be slightly off as they were calculated 
based on the wt. % of C and as the samples have some additional carbon from the residual 
surfactant. 
b
 Determined from elemental analysis.  
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2.2.2 Adsorption and release study  
 
By using the Beer-Lambert law, the amount of molecules adsorbed in the mesoporous 
samples or released by the samples was calculated. Although there was no significant difference 
in surface area and pore size (Table 2.1) between the four samples synthesized by post-grafting, 
the samples functionalized with vinyl and mercaptopropyl groups adsorbed significantly more 
rhodamine 6G than the samples functionalized with primary and secondary amines (Table 2.2 
and Figure 2.8). This trend was true also for samples synthesized by co-condensation. Upon 
comparing samples synthesized under similar conditions, the samples containing mercaptopropyl 
groups were found to adsorb more rhodamine 6G than the sample containing vinyl groups, which 
in turn adsorbed more than the amine-functionalized sample (Table 2.2). Generally, the 
adsorption capacity values for rhodamine 6G appeared to be the highest in the sample containing 
mercaptopropyl groups than vinyl groups and in samples synthesized by co-condensation than by 
post-grafting (Table 2.2). The adsorption capacity of the amine functionalized samples for 
rhodamine 6G was significantly lower. Careful analysis of the adsorption capacities by 
normalizing them with respect to the density of functional groups in the materials as well as their 
surface areas were conducted (Table 2.2). It indicated that the samples containing 
mercaptopropyl groups with grafting and co-condensation synthesis gave values of 1.5 x 10
-4 
and 
3.3 x 10
-4
 
mmol/m
2
, respectively, while those containing vinyl groups with grafting and co-
condensation gave 4.9 x 10
-5
 
mmol/m
2
 
and 6.8 x 10
-5
, respectively. The samples synthesized from 
APTS and BTSPA by grafting gave values of 1.1 x 10
-7
 
and 2.3 x 10
-7
mmol/m
2
, respectively. 
This indicates that the mercaptopropyl groups results in an order of magnitude higher adsorption 
capacity than those containing vinyl groups, which in turn showed two orders of magnitude 
higher than the amine functionalized samples. The rate of adsorption seems to be very similar in 
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all the samples in the initial period (for 0-11 h). The samples functionalized with VTS by post-
grafting as well as by co-condensation were almost saturated within 11 h. However, the samples 
functionalized with MPTS continued to adsorb rhodamine 6G for more than 11 h.  
The adsorption profiles plotted by measuring adsorption versus concentration are shown in 
Figure 2.8 (A). All the lines were fit to Y = A (1-e
-bX
), where A and b are constants (Table 2.3). 
The term A represents the maximum drug adsorption by the materials while the value of (bA) 
represents for the initial adsorption rate of the drug by the nanoparticles. Analysis of these terms 
A and b indicates that MPTS-functionalized samples have higher adsorption capacity than their 
corresponding VTS-functionalized samples in both cases, i.e. samples synthesized by either 
grafting or co-condensation. Furthermore, the data shows that the initial adsorption rates of the 
samples decrease in the order of Co-MPTS > Grafting-MPTS > Co-VTS = Grafting-VTS. 
 
Table 2. 3  Values of terms “A” and “b” in the graphs for adsorption versus concentration of 
rhodamine 6G that are fit into a function: Y = A (1-e
-bX
), where A and b are constants for each 
specific adsorption.  
 
Particles  A, % 
a 
 b, μmol-1L b  r2  
Co-MPTS  43  5 x 10
-4
  0.98  
Co-VTS  40  3 x 10
-4
  0.99  
Grafting-MPTS  55  2 x 10
-4
  0.98  
Grafting-VTS  30  4 x 10
-4
  0.99  
a
 The term A represents the maximum drug adsorption by the materials. 
b
 The term (bA)indicates 
the initial adsorption rate of the drug by the nanoparticles.  
 
 
 
 
45 
 
 
(A) 
 
 
 
(B) 
 
 
 
46 
 
 
(C) 
 
 
Figure 2. 8 Adsorption properties of rhodamine 6G in various functionalized mesoporous 
materials. (A) Adsorption versus concentration of R6G for samples synthesized by post-grafting 
and co-condensation. (B) Percent of R6G adsorbed versus time profile of different samples 
synthesized by post-grafting and co-condensation using aqueous 50 µM rhodamine 6G solution 
(C) Digital images showing colors of the functionalized mesoporous samples synthesized by 
post-grafting after adsorption of R6G.  
 
 
The adsorption results shown in Figure 2.8 were further complemented by comparing the 
weight losses between ~150-700 °C on thermogravimetric analysis (TGA) of the samples before 
and adsorption of R6G. The weight loss between ~150-700 °C is correlated or can correspond 
with decomposition of R6G or drug molecules. Figure 2.9 shows the TGA traces of the samples 
after incubation in 50 µM R6G solutions (or the samples shown in Figure 2.8 B). The TGA 
traces of sample Co-MPTS exhibited a 15.2% weight loss before adsorption of R6G adsorption 
and a 23.4% weight loss after adsorption of R6G (Figure 2.9 I). This corresponds to adsorbed 
R6G weight of 8.2 % and consistent with the adsorption capacity obtained in the adsorption 
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profile in Figure 2.8 B. The TGA traces of sample Co-VTS exhibited a 5.1% weight loss before 
rhodamine adsorption and a 10.0% weight loss after R6G adsorption (Figure 2.9 II). This 
corresponds to R6G weight of 4.9%, which is also consistent with the adsorption capacity of the 
sample obtained in Figure 2.8 B. The increase in the values of weight losses after adsorption of 
R6G clearly suggests that R6G was adsorbed in the samples and the difference between the two 
values corresponds to the amount of R6G adsorbed. These data indicate again that Co-MPTS 
adsorbed more R6G than Co-VTS and is consistent with the data obtained from the UV-Vis 
spectra analysis.  
 
(Ⅰ) 
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(Ⅱ) 
 
 
Figure 2. 9  Thermogravimetric (TGA) traces of before surfactant extraction (A), after surfactant 
extraction (B), and after R6G adsorption (C) for (I) samples synthesized by co-condensation of 
MPTS and (II) samples synthesized by co-condensation of VTS.  
 
The difference in the degree of adsorption of R6G by the samples can also be clearly seen by 
simply looking at the color of the mesoporous materials after treatment with R6G solution 
(Figure 2.8 C). After mixing the same mass mesoporous materials with the same volume and 
concentration of R6G solution for several hours and then separating the solid from the 
supernatant, samples with colors ranging from white to dark pink were obtained. While the 
samples functionalized with APTS and BTSPA still appear white, those functionalized with 
MPTS and VTS are deep pink in color. This indicates that the samples functionalized with APTS 
and BTSPA adsorbed little rhodamine 6G while the samples functionalized with MPTS and VTS 
by both methods adsorbed greater amount of R6G.  
Comparison of the density of functional groups in the materials with respect to their 
adsorption properties to R6G reveals an interesting trend. Although the density of grafted 
groups in the APTS functionalized sample is higher than that in the MPTS functionalized 
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sample, the former has a lower degree of adsorption of R6G. The adsorption capacity of the 
samples was normalized with the density of organic functional groups in the materials and 
their surface areas. It reveals that the differences in adsorption properties of the samples to 
rhodamine 6G could be partially attributed to the differences in the type of the functional 
groups and possible degree of interaction between the functional groups and R6G molecules. 
Recently Suh et al. 
54
 have made extensive studies in this area, which indicated that 
rhodamine based dyes with positive charges such as rhodamine 6G and rhodamine 123 show 
faster uptake than those with negative charges such as rhodamine 101. Their results 
suggested that the molecular charge of the drug has an important effect for the uptake rate of 
the drugs in the materials. This molecular-charge effect is the result of negative charges that 
are developed in the pore surfaces by the ionization of silanol groups in aqueous solution and 
their interactions with the charges of the incoming dye molecules. Among the positively 
charged dyes, both the molecular weight and the magnitude of the dipole moment seem to 
contribute to the diffusion kinetics of the dyes. Their study and that of Sekine and Nakatani 
59
 have also reported uptake half-lives of 10-30 min at room temperature depending on the 
solution pH, the ionic strength, the type of material (powder versus thin film) as well as the 
channel length and pore structures. We observed that the uptake half-times are slightly longer 
than what was observed by others, with the MPTS-functionalized samples reaching to uptake 
half-lives more slowly than the VTS-functionalized samples. However, the former gave 
higher overall uptake of rhodamine 6G than the corresponding VTS-functionalized sample. 
Generally, the MPTS-and VTS-functionalized samples gave higher adsorption capacity than 
MCM-41 and amine-functionalized sample. The functional groups such as mercaptopropyl 
and vinyl, which are hydrophobic, favorably interact with the hydrophobic parts of 
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rhodamine 6G, producing higher adsorption capacity to R6G compared to MCM-41 and the 
materials functionalized with organoamines. It appears that the hydrophilic organoamines, -
NH2 and -NH groups, in the APTS and BTSPA functionalized materials, respectively, 
produce unfavorable interaction with the aromatic and alkyl chains of rhodamine 6G 
molecule and thus, producing lower adsorption capacity to R6G. In fact, the amine functional 
groups would likely to be protonated by abstracting a proton from the silanol groups 
89
. This 
then leads to samples that have a positively charged surface which is not conducive for 
adsorption of positively charged R6G molecules. The amount of rhodamine 6G on the 
external area was calculated  to be 2.0-4.5% by subtracting the amount of rhodamine 6G 
removed in the washing steps from the total amount adsorbed initially. The total  loading of 
rhodamine 6G in the mesoporous channels is calculated to be 30-55 mg for 100 mg material.  
The trend in the degree of R6G release (Figure 2.10) by the functionalized samples was 
found to be the reverse of the one observed for adsorption. The studies of R6G release were 
conducted in a simulated body fluid (SBF) solution of pH of 7.40 at 37 ºC. 
37, 38
 SBF solution 
was chosen as it has similar composition as what is in our body and as it helps understanding 
how drug release properties of the materials would be in our body. The samples functionalized 
with VTS by post-grafting method released R6G molecules faster than the corresponding sample 
synthesized by co-condensation. On the other hand, the sample synthesized by post-grafting with 
MPTS released R6G molecules faster than the corresponding sample synthesized by co--
condensation, and the samples functionalized with VTS released R6G faster than the 
corresponding samples functionalized with MPTS.  
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Figure 2. 10  Comparative release profiles percent of R6G released for different samples 
synthesized by post-grafting and co-condensation of MPTS and VTS. The graphs were fitted as 
function Y = at
n
, where Y is % Release and t is time. This indicated that for samples grafted with 
MPTS, a = 0.0011, n = 2.6, r
2
 = 0.991; grafted with VTS, a = 0.16, n = 1.7, r
2
 = 0.991; sample 
Co-MPTS, a = 1.14 x10
-5
, n = 3.2, r
2
 = 0.990; and sample Co-VTS, a= 9.1 x 10
-4
, n = 2.9, r
2
 = 
0.987.  
 
 
The diffusional release data for R6G was fitted to a non-Fickian or a Super Case-II transport 
model 
37, 38
 and followed diffuisional release process that follow Equation (1) below with n > 1:  
                                                                      Y = at
n 
(1)                          (1) 
Where Y is % Release and t is time. Further analysis of the data and the graph in Fig. 6 gave 
values of a = 0.0011, n =2.6, r
2
 
= 0.991 for sample grafted with MPTS; a = 0.16, n = 1.7, r
2
 
= 
0.991 for sample grafted with VTS; a = 1.14 x10
-5
, n = 3.2, r
2
 
= 0.990 for sample Co-MPTS 
synthesized by co-condensation; and a = 9.1 x 10
-4
, n = 2.9, r
2
= 0.987 for sample Co-VTS 
synthesized by co-condensation.  
However, the adsorption experiments with ibuprofen (Figure 2.11 A) exhibited a totally 
different trend compared to the results obtained for adsorption of R6G for the same series of 
samples. The UV-Vis data showed that the samples functionalized with APTS and BTSPA by 
post-grafting had much more adsorption capacity for ibuprofen than for R6G. Furthermore, the 
sample grafted with APTS showed higher adsorption capacity of ibuprofen than the 
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corresponding sample grafted with BTSPA (Figure 2.11 A). On the other hand, the samples 
synthesized from MPTS and VTS, either by co-condensation or grafting, and the parent MCM-
41 showed almost no adsorption of ibuprofen (Figures not shown). The UV-Vis absorption 
results were corroborated by TGA data (Table 2.4 and Figure 2.11 B). These results are 
interesting considering the fact that elemental analysis (Table 2.2) shows the BTSPA-grafted 
sample has almost same number of grafted groups as the MPTS-grafted sample, but fewer than 
the VTS-grafted sample. This further indicates that the type of functional groups (or the degree 
of their interaction with ibuprofen) and not their density in the materials is mainly responsible for 
the differences in adsorption capacity of materials. Since ibuprofen contains a carboxylic acid 
group, these carboxylic acid groups could interact favorably with the -NH2 and -NH-groups in 
the amine-functionalized samples via hydrogen bonding, producing higher adsorption capacity of 
these samples for ibuprofen. On the other hand, the hydrophobic mercaptopropyl and vinyl 
groups in VTS and MPTS functionalized samples, respectively, have unfavorable interaction 
with ibuprofen, producing less adsorption capacity for ibuprofen. These results are consistent 
with those reported by others for similar functional groups. 
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Table 2. 4  Percent weight loss between 200-600°C for samples grafted with APTS and BTSPA, 
before and after adsorption of ibuprofen.  
 
Samples  Before adsorption  After ibuprofen adsorption  
Grafting APTS  11.8%  18.0%  
Grafting BTSPA  11.0%  16.2%  
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(A) 
 
(B) 
 
Figure 2. 11 Adsorption properties of ibuprofen by various amine functionalized mesoporous 
materials. (A) Percent of ibuprofen adsorbed versus time profile of samples synthesized by 
postgrafting. (B) Thermogravimetric analysis of mesoporous materials before and after 
adsorption of ibuprofen. 
 
The percent of adsorption of ibuprofen on the outer surface of the materials was obtained by 
soaking the samples in ibuprofen solution, then filtering and quickly washing the materials once 
with 20 mL ethanol 
67
. The value was found to be 3.6 and 9.8 % for the APTS and BTSPA 
functionalized samples, respectively. The corresponding total load of ibuprofen in 50 mg 
samples were 30.2 and 33.2 mg, respectively.  
The rate of drug release of ibuprofen by the samples functionalized with APTS and BTSPA 
were found to be essentially similar (Figure 2.12). The diffusional release data for ibuprofen 
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followed a Fickian diffusion process and it was fitted on the Higuchi equation
91-93
 (Y = at
n
), 
Where Y is % release, t is time, and k stands for the rate at which ibuprofen gets released by the 
particles. After peak fitting the data, we obtained n = 1 for t < t＊, where t＊
 
is a time constant 
when the release reaches equilibrium (A, i.e., the maximum release), and has values of 2.9 and 
3.3 h for APTS and BTSPA grafted samples, respectively (Equation 2) (Table 2.5):  
                                                             Y = k t                                                      (2)  
And n = 0 for t > t* (Equation 3):  
                                                               Y= 100                                                     (3)  
 
As can be seen above, the diffusional release of the two molecules, R6G and ibuprofen, from 
the functionalized materials follows different mechanisms. This may have to do with the fact that 
the interaction of R6G with the organic functional groups is dominated by hydrophobic 
interaction while the interaction between ibuprofen and the organoamine and residual silanol 
groups of the functionalized mesoporous materials is dominated by hydrogen bonding. Suh et al 
55
 reported that the control of the inclusion and release characteristics of drug molecules in 
mesoporous materials by manipulating the molecular interactions such as hydrogen bonding 
between the host and guest molecules is possible.  
 
Table 2. 5  Data of ibuprofen release shown in Figure 2.12 for APTS and BTSPA grafted 
samples after the graphs are fitted to Y = k t (if t < t*) or Y = A (if t > t*), where Y represents 
percentage of ibuprofen released, and t is time. t* is a time constant when the release reaches 
equilibrium (A, i.e., the maximum release), whereas k stands for the rate at which ibuprofen gets 
released by the materials.  
 
Samples  k (h
-1
) t* (h) A (%)  r
2
  
Grafting-APTS  34.2 2.9 100.3 0.95 
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Grafting-BTSPA  32.9  3.3  108.6 0.94 
 
  
 
Figure 2. 12  (A) Release of ibuprofen in SBF solution by different samples functionalized with 
APTS and BTSPA. The graph for sample Grafting APTS was fitted as Y =kt
1/2
 (t < 2.6), Y = 100 
(t > 2.6), r
2
 = 0.996 and the graph for sample Grafting BTSPA was fitted as Y =kt
1/2
 (t < 2.6), Y 
= ~ 100 (t > 2.6), r
2
 = 0.996.  
 
Although our FT-IR spectra (Figure 2.16) did not conclusively reveal any possible such 
interaction and while Suh et al. 
55
 have also not performed such an experiment, we believe that 
similar interactions as proposed by Suh et al. 
55
 may have also play roles in the differences in 
adsorption capacity and release properties among our materials. In another report by Vallet-Regí 
and co-workers 
32, 33
, not only the functional groups but also the loading of drug or the drug: host 
ratio is reported to also play important role for drug release kinetics. Interestingly, the drug 
release profiles of our samples seem to show unusually slower drug release followed by faster 
release. This kind of release profile is peculiar and, to our best knowledge, has never been 
reported for mesoporous materials. However, we do not know what its underlying mechanism, 
which may warrant further investigations.  
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2.3  Supplementary of Characterization Results and Information 
 
Table 2. 6  Percent weight loss between 100-550 °C and mmol/organic groups/g sample for the 
functionalized mesoporous samples synthesized by co-condensation.  
 
  
Sample  Wt. % of Organic Groups  
APTS  6.5%  
BTSPA  6.0%  
MPTS  14.0%  
VTS  4.5%  
 
 
2.3.1 Solid-state NMR spectra (
29
Si CP-MAS) of various functionalized mesoporous 
samples 
 
(A)Grafting-APTS 
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(B) Grafting-BTSPA 
 
 
 
 
(C) Grafting-MPTS 
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(D) Grafting-VTS 
 
 
 
 
(E) Co-MPTS 
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(F) Co-VTS 
 
 
 
Figure 2. 13   
29
Si CP-MAS NMR spectra of various functionalized mesoporous samples. 
 
2.3.2 Solid-state NMR spectra (
13
C CP-MAS) of functionalized mesoporous sample 
 
(A) Grafting-APTS 
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(B) Grafting-BTSPA 
 
 
 
 
 
(C) Grafting-MPTS 
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(D) Grafting-VTS 
 
 
 
 
 
(E) Co-MPTS 
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(F) Co-VTS 
 
 
 
Figure 2. 14   
13
C CP-MAS NMR spectra of functionalized mesoporous samples 
 
2.3.3 Thermogravimetric (TGA) traces of various functionalized    mesoporous materials 
 
 
(A) 
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(B) 
 
 
 
 
 
(C) 
 
 
 
(D) 
 
 
 
 
Figure 2. 15  Thermogravimetric (TGA) traces of various functionalized mesoporous materials  
 
 
2.3.4 FT-IR spectra of various functionalized mesoporous materials 
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Figure 2. 16  FT-IR spectra of representative functionalized samples (A) before R6G adsorption 
and (B) after R6G adsorption. 
 
2.4 Conclusion 
 
The adsorption capacity and release properties of mesoporous materials for different drug 
molecules can be improved by functionalizing them with judiciously chosen organic groups. 
Rhodamine 6G and ibuprofen, which have different structures and surface properties, were used 
as model drug molecules to conduct comparative adsorption and release properties of organic 
functionalized mesoporous materials that were synthesized by post-grafting and co-condensation. 
65 
 
While mesoporous samples functionalized with mercaptopropyl and vinyl groups showed 
improved adsorption capacity for rhodamine 6G, samples functionalized with primary and 
secondary amine groups that were synthesized by grafting and co-condensation methods 
exhibited less adsorption capacity for rhodamine 6G. On the other hand, the trend in the degree 
of adsorption of ibuprofen was found to be the reverse of the results obtained for rhodamine 6G. 
The samples containing mercaptopropyl and vinyl groups showed less adsorption capacity for 
ibuprofen than the samples functionalized with primary and secondary amine groups. The release 
of the adsorbed molecules was also found to be dependent on the type of functional groups in the 
materials. The method of tuning adsorption capacity and release properties by organic 
functionalization of mesoporous materials could be extended to other organic functional groups 
and to a variety of other drug molecules. The resulting functionalized mesoporous materials may 
help to deliver drugs efficiently and, thus, minimize the drugs’ possible adverse effects. 
Introducing secondary bioactive groups onto the external surface of the materials may also allow 
targeted delivery of the drug cargo to specific cells.  
2.5  Experimental Section 
2.5.1 Materials and reagents  
 
Tetraethoxysilane (TEOS), 3-aminopropyltriethoxysilane (APTS), rhodamine 6G (R6G), 
cetyltrimethyammonium bromide (CTAB), ibuprofen sodium salt, 3-
mercaptopropyltrimethoxysilane (MPTS), vinyltrimethoxysilane (VTS), NaCl, NaHCO3, KCl, 
K2HPO4·3H2O, MgCl2·6H2O, CaCl2, Na2SO4, NH2C(CH2OH)3, and 
bis(triethoxysilylpropyl)amine (BTSPA) were obtained from Sigma-Aldrich. Hydrochloric acid 
(36.5%) and anhydrous toluene were purchased from Fisher Scientific.  
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2.5.2 Synthesis of Functionalized Mesoporous Materials via Co-condensation  
 
A solution of 33.4 mL of distilled water and 15 mL of ammonium hydroxide was prepared 
and 2.30 mmol of CTAB was dissolved in it by stirring. Then, a mixture of 17 mmol TEOS and 
3.0 mmol of one of the organosilanes (MPTS, VTS, APTS, or BTSPA) was added. The solution 
was stirred at room temperature for 2 h and then stored in oven at 80 °C for 2 days. The sample 
was cooled to room temperature and filtered using Whatman-1 filter paper. The solid was 
washed thoroughly with large amount of distilled water and dried under ambient condition 
resulting in organicfunctionalized mesostructured materials containing 3-mercaptopropyl, vinyl, 
3-aminopropyl, or N, N-diproplyamine groups, respectively. The surfactant template was 
extracted by stirring 2 g of the functionalized mesostructured material with a solution of 50 mL 
methanol and 10 mL HCl for 5 h at 50 °C. The solution was filtered using Whatman-1 filter 
paper. The solid was washed three times with 20 mL of methanol and dried under vacuum for 30 
min. This resulted in organic functionalized samples that were denoted as Co-MPTS, Co-VTS, 
Co-APTS, and Co-BPSPA, which contained 3-mercaptopropyl, vinyl, 3-aminopropyl, or N, N-
diproplyamine groups, respectively. 
 
Figure 2. 17  Chemical structure of orgasilica precursor and organosilanes 
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2.5.3  Synthesis of Functionalized Mesoporous Materials via Post-Grafting  
 
First, mesoporous silica was prepared and then functionalized with different organic groups. 
Typically, a solution of 960 mL distilled water, 10.9 mmol CTAB and 40 mL NaOH (2.0 M) was 
prepared at 80 °C. The solution was stirred at 80 ℃ for 30 min. After adding 22.6 mL of TEOS, 
the solution was stirred for 2 h at 80 °C. It was then filtered using Whatman-1 filter paper and 
the solid was washed thoroughly with copious amount of distilled water, and dried under 
ambient condition. The surfactant template was extracted by stirring 1 g of the functionalized 
mesostructured material with a solution containing 150 mL ethanol and 0.6 mL HCl for 5 h at 
50 °C to produce mesoporous silica, MCM-41. It was dried at 80 °C for 4h before being used for 
grafting. The extracted MCM-41 was grafted with 3mercaptopropyl, vinyl, 3-aminopropyl, and 
secondary amine groups by stirring 600 mg MCM-41 with 4.4 mmol of MPTS, VTS, APTS, or 
BTSPA, respectively, in 100 mL toluene at 78 °C for 5 h. The samples were then washed with 
copious amount of ethanol and let to dry under ambient condition. The MCM-41 to organosilane 
ration of 600 mg/4.4 mmol was chosen in order to ensure that excess organosilane is present in 
the solution. Many of our and others’ previous studies 44, 45 have shown that this ratio is optimum 
for obtaining the maximum possible grafted groups in the materials.                                                                                                                         
2.5.4  Adsorption of Rhodamine 6G  
 
Typically, a solution of 50 µM rhodamine 6G dye was prepared in distilled water at room 
temperature. Then, 100 mg of the the organic-functionalized mesoporous sample and 50 mL of a 
50 µM rhodamine 6G solution were mixed and stirred. At 30 min intervals, the solution was 
centrifuged for 5 min and then the supernatant was analyzed with UV-Vis absorption 
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spectroscopy, by measuring adsorbance at 534 nm, which corresponds to the absorption 
maximum of rhodamine 6G. Additional absorption measurement was repeated, until the sample 
had stopped adsorbing more dye or until the absorption spectra of the supernatant had barely 
changed, indicating equilibrium was reached. Upon nearly complete adsorption of rhodamine 6G 
from the supernatant by the material, more rhodamine 6G solution was added into the sample 
and the above procedure was repeated.  
In another experiment, 50 mg different functionalized samples were mixed with different 
concentrations of rhodamine 6G solutions and kept for 2 days, and after centrifugation, the 
absorbance of the supernatant was measured. This allowed us to plot adsorption versus 
concentration Figure 2.8 (A), which allowed us to determine the adsorption capacity of the 
samples. 
2.5.5  Release of Rhodamine 6G  
 
The experiments involving rhodamine 6G release by the samples were performed in a 
simulated body fluid (SBF) solution at 37 °C 
37, 38
. The SBF solution was prepared by mixing 
NaCl (0.14 mol), NaHCO3 (4.20 mmol), KCl (3.00 mmol g), K2HPO4·3H2O (1 mmol), 
MgCl2·6H2O (1.50 mmol), 1 N HCl (40 mL), CaCl2 (2.50 mmol), Na2SO4 (0.50 mmol), and 
NH2C(CH2OH)3 (49.90 mmol). A rhodamine 6G saturated sample was first prepared by mixing 
100 mg of the functionalized mesoporous samples with 50 mL volume of 50 µM of rhodamine 
6G solution until the mesoporous sample stopped adsorbing more rhodamine 6G, as monitored 
by UV-Vis absorption spectroscopy. The solution was filtered and the solid was washed with 20 
mL of water. This washing procedure was used to remove excess rhodamine 6G molecules on 
the outer surface of the materials 
67
. The amount of rhodamine 6G on the external area was 
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calculated to be 2.0-4.5% by subtracting the amount of rhodamine 6G removed in the washing 
steps from the total amount adsorbed initially. The total loading of rhodamine 6G in the 
mesoporous channels is calculated to be 30 – 55 mg for 100 mg material (Table 2.2). Then, 100 
mg of rhodamine 6G saturated samples was mixed 50 mL SBF solution of pH 7.4 at 37 °C and 
stirred for 2 h. The solution was centrifuged for 5 min and then the UV-Vis absorption of 5 mL 
of the supernatant was tested by UV-Vis spectroscopy, by monitoring the absorption maximum 
of rhodamine 6G at 534 nm. The SBF/rhodamine 6G supernatant solutions used for the 
measurement was discarded and the same volume of a fresh SBF solution was then added into 
the sample. After stirring and centrifugation of the solution, by following the same procedure 
above, the supernatant was analyzed again by UV-Vis spectroscopy. This experiment was 
repeated until the release of rhodamine 6G by the sample remained insignificant.   
2.5.6  Adsorption of Ibuprofen  
 
With the same functionalized mesoporous materials, adsorption and release experiments with 
ibuprofen were performed. First, ibuprofen was prepared by stirring 4.4 mmol of commercially 
available ibuprofen sodium salt in 40 mL, 0.2 M HCl solution overnight at room temperature. 
The ibuprofen was let to crystallize. The solution was then filtered over Whatman-1 filter paper 
and the solid ibuprofen was dried under vacuum for 30 min. A solution of ibuprofen with a 
concentration of 2.2 mM in ethanol was prepared. The UV-Vis adsorption experiments were 
carried out with this solution by following the procedure mentioned above for rhodamine 6G but 
by monitoring the absorption maximum of ibuprofen at 264 nm. To determine the % of 
adsorption of ibuprofen on the external surface of the materials, 50 mg of functionalized 
mesoporous sample was soaked in 50 mL of 24.2 mM ibuprofen solution for 24 h. It was then 
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filtered and quickly washed once with 20 mL ethanol to remove excess ibuprofen coating on the 
outer surface of the materials 
67
. The amount of ibuprofen on the external area was calculated by 
subtracting the amount of ibuprofen removed in the washing steps from the total amount 
adsorbed initially.  
2.5.7  Ibuprofen Release Experiments  
 
Typically, 50 mg of the functionalized mesoporous sample that was saturated with ibuprofen 
above was stirred in 10 mL of SBF solution at pH 7.4 at 37 °C. After centrifugation of the 
sample for 5 min, 5 mL of the supernatant was tested with UV-Vis every 30-60 min to ensure 
that the mesoporous sample was saturated with ibuprofen. The release experiments were 
generally carried out by following the same procedure as the one carried out for rhodamine 6G 
above, except monitoring the absorption maximum of ibuprofen at 264 nm.  
2.5.8  Characterization  
 
The UV-Vis absorption spectra were measured with a Lambda-950 spectrophotometer 
(PerkinElmer). The thermogravimetric (TGA) traces were collected by using a Q-500 
Quantachrome Analyzer (TA-Instruments) with N2 (99.999 %) as a carrier gas with a heating 
ramp of 5 ºC/min. The low angle powder X-ray diffraction (XRD) patterns were obtained with a 
Scintag Diffractometer. The BET gas adsorption-desorption measurements were done with 
Micromeritics Tristar 3000 volumetric adsorption analyzer, after degassing the samples at 
160 °C for 12 h. The solid-state 
13
C (75.5 MHz) and 
29
Si (59.6 MHz) NMR spectra were 
acquired on a Bruker AVANCE 300 NMR spectrometer. For 
13
C CP-MAS NMR experiments, 
7.0 kHz spin rate, 5 s recycle delay, 1 ms contact time, π/2 pulse width of 5.6 μs, and 600 scans 
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using TPPM 
1
H decoupling were employed. For the 
29
Si  CP-MAS NMR experiments, 7.0 kHz 
spin rate, 10 s recycle delay, 10 ms contact time, π/2 pulse width of 5.6 μs, and 600 scans by 
using TPPM 
1
H decoupling were employed.  
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CHAPTER 3  RHODAMINE 6G AND IBUPROFEN ADSORPTION AND 
RELEASE STUDY OVER SBA-15 
 
3.1 Introduction and Background 
 
Among mesoporous materials, SBA-15 has large surface area, large pore size, and thick 
walls 
1-3
.  It possesses a hexagonal array of mesopores 6.0-20 nm in diameter, which is much 
larger than the 3.0-nm pores characteristic of the MCM-41 and MCM-48. Their wall thickness is 
an important parameter for providing a high degree of hydrothermal stability and improved 
mechanical stability compared to mesoporous MCM-41 and related silicas 
4
,  and thus a 
sufficiently long lifetime in biological environments.
5
 Therefore, SBA-15 mesoporous materials 
could be modified with various surface functional groups and still preserve the large pore 
channels and surface areas for drug adsorption and desorption after modification.
6-10
 We already 
investigated adsorption and release of R6G and ibuprofen over different MCM-41 of various 
functional groups, either hydropholic or hydrophobic. Here we carried out the same study but 
over SBA-15 mesoporous materials, i.e. extracted SBA-15, SH-SBA-15 and COOH-SBA-15 and 
we studied the effect of functional groups. To learn how pore size affects the adsorption and 
release of drug and the difference of these properties between SBA-15 and MCM-41, carboxylic 
acid modified mesoporous materials were chosen as the carrier for this study.  We consider that 
this acid group can have electrical interaction with the amine group of R6G and thus will have 
significant adsorption and release, making it better for the study. 
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   Figure  3. 1 Structure of Rhhodamine 6G and ibuprofen used in the study 
 
 In order to measure adsorption or uptake, nanomaterials were mixed into solutions of 
adsorbate of known concentration and kept mixed for 48 hours.  As seen by desorption 
experiments results discussed below, 48 hours is long enough time to establish equilibrium 
between drug in solution and adsorbed drug.  At various time intervals, samples were taken and 
centrifuged.  The supernatant was separated and added into a cuvette, and analyzed by UV-Vis to 
obtain the adsorbate concentration (see Section 3.4.6 for details).  The adsorption can be 
calculated based on Lambert–Beer law, which relates the absorption of light to the properties of 
the material through which the light is traveling. For liquid, it is described as A=cL, A is 
absorbance,  is molar absorptivity and L is the light path length.  This implies that the 
absorbance becomes linear with the concentration of the solution under test. Thus, if the path 
length and the molar absorptivity are known and the absorbance is measured, the concentration 
of the solution can be deduced. Thermogravimetric analysis (TGA) was also used to confirm the 
adsorption. Samples before loading adsorbate and after loading adsorbate were analyzed by TGA 
and weight loss between 200-600 °C can be obtained. The weight loss difference indicates that 
drug molecules are really loaded onto the nanomaterials because this difference was the weight 
loss resulting from adsorbate loaded in the nanomaterials.  
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For release measurements, we mixed nanomaterials with solutions of known 
concentration for 48 h with stirring.  The amount of drug adsorbed under these conditions was 
known from previous adsorption experiments.  The loaded nanomaterials were separated from 
the solution by filtration and oven dried.  Then they were mixed with SBF (Simulated Body 
Fluid).  At various time intervals, samples were taken, centrifuged, and UV-Vis measurements 
were done on the supernatant to establish drug concentration in solution. 
When nanoparticles possibly containing drug are in contact with a solution possibly 
containing drug, there is the possibility of drug transfer from particles to solution and also from 
solution to particles.  In the simplest model, both these processes are first order with rate 
proportional to concentration.  Let c(t) represent the solution drug concentration in moles per 
liter at time t and a(t) the drug concentration in the nanoparticles in moles of drug per gram of 
nanoparticles at time (t) so 
ca
dt
dc
ad kk      (1) 
where kd is the desorption rate constant and ka the adsorption rate constant.  Units of kd are (g 
nanomaterial)(L solution)

t

, units of ka are t

. 
In an adsorption experiment, a(0) = 0 and am + cV = coV where m is the mass of 
nanomaterial in grams and V is the volume of solution in liters.  Also, co = c(0) = initial drug 
concentration in solution.  Equation (1) may be integrated to 
  c = co
)(
)(
da
d
)]t([
a
da
V/mkk
V/mkek
V/mkk


    (2) 
At t = 0, c = co and at t  ,  
c  
da
odc
k
V
m
k
k

   and   a  
da
oac
k
V
m
k
k

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and a/c  (ka / kd) as t  .   Thus at equilibrium the concentration of adsorbed drug a is 
proportional to the concentration of drug remaining in solution c.  The unitless equilibrium 
constant is defined as Keq = (m/V)(a/c).  To discuss release experiments, again start with 
equation (1) but with c(0) = 0 and a(0) = com/V.   Then integration of equation (1) gives 
 c(t) = co  t])([
da
d da1
)(
)( V/mkk
e
V/mkk
V/mk 

 (3) 
so that c() = kd co /[ka(m/V)+kd] again, and a/c  (ka / kd) = Keq (V/m) as t  .   
 If in an adsorption experiment the concentration of drug left in solution after equilibrium 
is c, the adsorbate has adsorbed (co  c)V moles so that a = a = (co  c)V/m.  Therefore 
m
V
m
V
eq
o K 
c
cc
c
a






     (4) 
so that equilibrium constant is easily calculated from concentrations before and after adsorption. 
As shown below, Keq can also be obtained from a release experiment, in which material 
previously loaded with drug is suspended in liquid and concentration of drug in liquid after long 
time is measured.   
3.2 Results and Discussion 
3.2.1 Characterization 
3.2.1.1 Powder X-ray Diffraction  
 
 
The X-ray diffraction (XRD) patterns of one of the functionalized mesoporous materials (Ex-
SBA) are shown in Figure 3.2 I, II. The X-ray diffraction (XRD) patterns exhibited hexagonally 
ordered mesoporous structure that is characteristic of SBA-15. Furthermore, there is a slight 
decrease in their (100) Bragg reflection after R6G adsorption and no obvious decrease for 
ibuprofen adsorption.  The samples remained mesostructured with the unit cell size changing a 
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little after adsorption and release of rhodamine 6G (R6G) and ibuprofen (Figure 3.2 I, II). The 
decrease in the intensity of Bragg reflection is probably a result of a slight decrease in electron 
contrast between the mesopores and the mesopore channel walls due to the confinement of the 
R6G and ibuprofen guest molecules inside the mesopores 
11
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Figure  3. 2  (I) XRD of Ex-SBA (A) Before R6G adsorption, (B) After adsorbing R6G, (C) 
After R6G release study; (II) XRD of Ex-SBA (A)  Before ibuprofen adsorption, (B) After 
adsorbing ibuprofen, (C) After ibuprofen release study. 
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3.2.1.2  Thermogravimetric analysis (TGA) 
 
 
The mesoporous materials were further characterized by thermogravimetric analysis under 
nitrogen (Table 3.1, Table 3.2 and Figure 3.3). Thermogravimetric analysis of organic 
functionalized mesoporous materials under nitrogen or air were previously used by many groups 
for characterization of organic functionalized mesoporous materials 
12-15
.   Our results further 
corroborated the results obtained from UV-Vis data. The TGA traces of the functionalized 
samples (Figure 3.3) showed a weight loss below 100°C due to physisorbed water 
16
 while 
weight loss between ~200-600°C resulted from the loss of organic functional groups. In addition, 
there was a slight weight reduction after 600 °C because of the loss of water molecules from 
condensation of residual silanols. The order of adsorption and release capacity for the different 
functionalized silica particles are the same as calculated from UV-Vis data on the whole. The 
weight loss (%) of drug loaded samples before and after release is summarized in Table 3.1 and 
Table 3.2. By subtracting the weight loss of samples after release from that of the same 
functionalized samples before release, the amount of released drug can be calculated. It is 
summarized in Table 3.1 and Table 3.2. For R6G loaded samples, R6G load percent is 0.5% for 
Ex-SBA, 1.69% for SH-SBA and 4.12% for COOH-SBA and it decreases in the order of COOH-
SBA> SH-SBA >Ex-SBA. This is the same as showed from UV-Vis data (see the following 
discussion). For ibuprofen loaded samples, load percent is 16.8% for Ex-SBA, 2.6% for SH-SBA 
and 9.0% for COOH-SBA. This shows that the ibuprofen adsorption amount decreases after -SH 
and -COOH group modification which is completely different from R6G adsorption case. It is 
reasonable because -SH is hydrophobic from our previous study and thus is not good for the 
hydrophilic ibuprofen attraction. For-COOH modified sample, it may be due to the repulsion 
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between the same charges and thus has low loading amount comparing with the parent Ex-SBA 
sample. 
 
 
Table 3. 1  Weight losses (%) between 200-600 °C of samples loaded with R6G 
 
 Ex-SBA 
SH-SBA 
 
 
COOH-SBA 
 
Before release 6.12 31.11 16.87 
After release 5.62 29.42 12.75 
Amount loaded 0.50 1.69 4.12 
 
 
 
Table 3. 2  Weight losses (%) between 200-600 °C of samples loaded with ibuprofen 
 Ex-SBA 
SH-SBA 
 
 
COOH-SBA 
 
Before release 22.8 31.1 19.5 
After release 5.98 28.5 10.5 
Amount loaded 16.8 2.6 9.0 
 
 
(A) 
 
 
 
 
 
 
(B) 
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Figure 3. 3 Thermogravimetric (TGA) traces of various functionalized mesoporous materials 
before and after drug (R6G) release. (A) R6G-loaded Ex-SBA, (B) R6G-loaded SH-SBA, (C) 
R6G-loaded COOH-SBA, (D) Ibuprofen-loaded Ex-SBA, (E) Ibuprofen-loaded SH-SBA and (F) 
Ibuprofen-loaded COOH-SBA. 
 
 
3.2.2 Adsorption study of Rhodamine 6G and ibuprofen over functionalized mesoporous 
materials 
First, 1000µM solution of R6G and 10mg/ml solution (in hexane) of ibuprofen were prepared. 
Then 100 mg MCM-41 and SBA-15 materials were mixed with 10 ml of R6G or ibuprofen 
solutions prepared above, respectively. After 48 hours, the concentration of R6G remaining in 
the solution (original concentration 1000 M) are 654 µM, 338 µM, 193 µM, and 674 µM for 
Ex-SBA, SH-SBA, COOH-SBA and COOH-MCM respectively. For functionalized SBA 
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samples, Ex-SBA adsorbs 34.6% of the R6G and SH-SBA adsorbs 66.2% of the R6G from 
solution at equilibrium (See the bar graphs below.)  Thus, SH-SBA adsorbed more R6G than Ex-
SBA which shows that thiol functionalized group help to improve the adsorption capacity of 
SBA for R6G. This result is consistent with Thiol functionalized MCM study.
17
 Carboxylic 
grafted SBA adsorbs 80.7% of R6G in solution, which is more than that of SH-SBA and 
indicates –COOH group is even better than –SH for the adsorption of R6G. The adsorption order 
for R6G is COOH-SBA> SH-SBA >Ex-SBA (Table 3.1 and Figure 3.4 A, B).  This is consistent 
with the strength of interaction between R6G and grafted organic group. The functional 
mercaptopropyl group is hydrophobic and favorably interacts with the hydrophobic parts of 
rhodamine 6G, producing higher adsorption capacity for R6G compared to SBA without 
functional group. On the other hand, ibuprofen molecule contains a carboxylic acid group and 
carboxylic acid group could interact favorably with -NH- groups in the R6G molecule via 
hydrogen bonding and electronic attraction, producing adsorption capacity of R6G even higher 
than mercaptopropyl grafted SBA sample.  
 
(A) 
 
0
20
40
60
80
100
Ex-SBA SH-SBA COOH-SBA
A
d
s
o
rp
ti
o
n
 %
 
 
 
 
 
 
 
93 
 
(B) 
 
 
(C) 
0
10
20
30
40
50
60
70
80
90
COOH-SBA MCM-COOH
A
d
s
o
rp
ti
o
n
 %
 
 
 
(D) 
 
 
 
Figure  3. 4  (A) Percentage of R6G in solution adsorbed by 100 mg Ex-SBA, SH-SBA and 
COOH-SBA materials, (B) µmol of R6G adsorbed by per gram Ex-SBA, SH-SBA and COOH-
SBA of materials, (C) Percentage of R6G in solution adsorbed by 100 mg Ex-COOH-SBA and 
COOH-MCM materials and (D) µmol of R6G adsorbed by per gram COOH-SBA and COOH-
MCM  materials. 
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The table below shows the results and the calculated equilibrium constants Keq of the below 
equation for adsorption of R6G over the four materials.   
 
Values of Keq are in the same order as per cent adsorption from solution.  However, Keq 
varies much more in magnitude than per cent adsorption. 
Table 3. 3  Results of R6G adsorption measurements (original R6G concentration = 1000 M).  
Material Ex-SBA SH-SBA COOH-SBA COOH-MCM 
Concentration 
remaining, M 
654 338 193 674 
Keq 0.529 1.959 4.18 0.484 
 
To investigate how pore size affects the adsorption of R6G into nanomaterials, SBA-15 and 
MCM-41 type materials were compared as carriers.  Carboxylic functionalized materials were 
chosen since carboxylic acid grafted samples have highest adsorption capacity for R6G.  Figure 
3.4, C and D, shows COOH-SBA sample has more R6G adsorption than COOH-MCM sample, 
i.e. 80.7% of R6G in the solution was adsorbed by the former and 32.6% of R6G in the solution 
was absorbed by the latter. The values of Keq is 8.6 times greater for COOH-SBA than for 
COOH-MCM (Table 3.3).  This is due to physical parameters of the parent SBA-15 and MCM-
41.. SBA-15 has pore size up to 300Å while MCM-41 pore size is up to 100 Å, while MCM-41 
has larger surface area, around 1000m
2
/g, and SBA-15 has only 500-600 m
2
/g
18
 .  Considering 
they have the same -COOH functional group, the main reason for the larger adsorption by SBA-
15 must be the bigger pore size, making it easier for R6G to enter SBA-15. 
Besides R6G adsorption, ibuprofen adsorption was investigated over these functionalized 
mesoporous materials. The concentration of Ibuprofen remaining in the solution is 6.49 mg/ml, 
95 
 
8.01mg/ml, 8.20 mg/ml for Ex-SBA, SH-SBA, COOH-SBA and 8.75 mg/ml for COOH-MCM 
(original concentration, 10 mg/ml) (Table 3.4 and Figure3.5 A, B). For functionalized SBA 
samples, Ex-SBA adsorbs 35.1% of ibuprofen in solution while SH-SBA adsorbs 19.9% of 
ibuprofen from solution. So, SH-SBA loaded less ibuprofen, showing thiol functionalized group 
reduced adsorption capacity of ibuprofen. This result is consistent with our previous thiol 
functionalized MCM study.
17
 Carboxylic acid grafted SBA adsorbs 18% of ibuprofen in the 
solution, which is less than that of SH-SBA and Ex-SBA and indicates -COOH group also 
reduces the adsorption of ibuprofen. The adsorption amount of ibuprofen decreases in the order 
Ex-SBA > SH-SBA > COOH-SBA   The reason may be that ibuprofen can form hydrogen 
bonding with -OH in the channel of Ex-SBA, while SH-SBA has less -OH group for forming 
hydrogen bonding and -SH group is hydrophobic and has weak interaction with the ibuprofen 
which has a hydrophilic -COOH group. For COOH-SBA, the attraction is even weaker because 
carboxylic groups in SBA channel and carboxylic groups of ibuprofen molecules have the same 
charge and thus will repel each other. 
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Figure  3. 5  (A) Percentage of ibuprofen in solution adsorbed by 100 mg Ex-SBA, SH-SBA and 
COOH-SBA materials, (B) mmol of ibuprofen adsorbed per gram of Ex-SBA, SH-SBA and 
COOH-SBA , (C) Percentage of ibuprofen in solution adsorbed by 100 mg Ex-COOH-SBA and 
COOH-MCM materials and (D) mmol of ibuprofen adsorbed per gram COOH-SBA and COOH-
MCM  materials. 
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To investigate how pore size affects ibuprofen adsorption, the same carboxylic acid grafted 
SBA-15 and MCM-41 were used as for the R6G adsorption study. Figure 3.5, C shows COOH-
SBA sample has more ibuprofen adsorption than COOH-MCM sample. About 18.0% of 
ibuprofen in the solution was adsorbed by the former and around 12.5% was absorbed by the 
latter (see Figure 3.5, D). The size difference between these two mesoporous silica materials 
plays a crucial role for the adsorption capacity as for the R6G adsorption study above.   
Table 3. 4 Results of ibuprofen adsorption measurements (original ibuprofen concentration = 10 
mg/ml)  
Material Ex-SBA SH-SBA COOH-SBA COOH-MCM 
Concentration 
left, mg/ml 
6.49 8.01 8.20 8.75 
Concentration 
absorbed, mg/ml 
3.51 1.99 1.80 1.25 
 
Equilibrium constants Keq were calculated for ibuprofen adsorption by all the samples 
(Tables 3.4) and compared with Keq for R6G adsorption (Table 3.5), Keq for R6G adsorption is 
bigger than Keq for ibuprofen adsorption in every case, but the ratio is far from constant.  It is 1.5 
for EX-SBA, and more than 23 for COOH-SBA.   
Table 3. 5  Drug adsorption equilibrium constant (Keq) of the nanomaterials 
Keq EX-SBA SH-SBA COOH-SBA COOH-MCM 
R6G 0.529 1.959 4.18 0.484 
Ibuprofen 0.541 0.248 0.220 0.143 
3.2.3 Release study of Rhodamine 6G and ibuprofen over functionalized mesoporous 
materials 
For the release studies, 1000µM solution of R6G and 10mg/ml solution (in hexane) of 
ibuprofen were prepared first. Then, 100 mg MCM-41 or SBA-15 materials were mixed with 
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10ml of R6G or ibuprofen solutions prepared above, respectively, for 48h.  The drug-saturated 
materials were removed, and mixed with 10 ml solvent at t = 0.  Solution drug concentration was 
measured as a function of time t   Shown in the desorption graphs below (Fig.3.6, Fig 3.7) is 
solution concentration as function of sampling time. Concentration has leveled off well before 48 
hr in every case.   
 
Plots of release amount of R6G, in mol per gram nanomaterial, vs. time are given in Figure 
3.6.  Figure 3.6 also shows the best fits of release amount R to the function 
   )e 1( QtAR       [5] 
(see Eq. 3) which guarantees R = 0 at t = 0 (initial time) and gives A as the maximum amount 
released.  It is clear that, after 5 h, the release amounts of R6G from all three SBA samples have 
approached the maximum. 
The parameters A and Q of the above equation for R6G release were obtained after fitting the 
release curves and are summarized in Table 3.6. According to equation (3), 
   A = co
mVkk
mVk
da
d
/
/

 = co
1K
1
eq 
 
Since A is c this shows that Keq = (co/ c)  1.  Here co is the total amount of drug (in solution 
and adsorbed), expressed as a concentration. Therefore the equilibrium constant Keq can be 
calculated from the following equation: 
Keq= (1f)/f 
where f is the fraction of the drug released of the total drug loaded in the nanomaterials (f = 
c/co). Calculated equilibrium constants (Keq) are summarized in Table 3.6, last line.  
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Table 3. 6 Overall results for R6G release test 
 
 
 
 
 
 
 
 
The maximum release amount of R6G from the SBA samples is 4.57 M/g material for Ex-
SBA, 0.250 M/g material for SH-SBA, and 14.4 M/g material for COOH-SBA (see Table 3.6).  
The maximum release amount decreases in the order COOH-SBA > Ex-SBA > SH-SBA.  The 
per cents released, 13.2%, 0.377%, and 17.9%, are in the same order.  The order is not the same 
for the equilibrium constants, Keq.   
COOH-SBA has highest release amount and release percentage. SH-SBA has less release 
amount and less release percentage than Ex-SBA. This can be explained from the interaction 
between the SBA and drug molecules. The reason is that for COOH-SBA, the interaction 
involves hydrogen bonding and electronic attraction. When drug is released, hydrogen bonding is 
broken and so R6G can easily escape without the attraction by COOH group.  
Values of Keq (Table 3.6) are significantly larger than corresponding values of Keq from 
adsorption measurement, except for COOH-SBA (Table 3.5).  This may be because some 
amount of adsorbed drug in the materials can not escape, so it is not in equilibrium with solution.  
Note that, before release study, drug-loaded nanoparticles were kept in oven for at least 48 hours 
Material Ex-SBA SH-SBA COOH-SBA COOH-MCM 
A (mol /g material) 4.57 0.250 14.4 1.76 
Q (see equation 5) 0.465 1.28 3.53 6.26 
Total adsorbed (mol/g) 34.6 66.2 80.7 32.6 
f = fraction released 0.132 0.00377 0.179 0.0540 
Keq = equil. constant 6.57 263.8 4.60 17.5 
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to dry.  During this process the bonding of drug to nanoparticles may be changed, or the structure 
of the nanomaterials may be changed, preventing escape of some of the drug from the materials.    
After we fitted the release curve, the release rate of R6G from each sample was calculated. 
According to [5], 
     QtAQ
t
R  e
d
d
 
the initial rate is AQ.  Using data in Table 3.6, release rates from Ex-SBA, SH-SBA, COOH-
SBA, and COOH-MCM are 2.13 mol/g/h, 0.320 mol/g/h, 50.8 mol/g/h, and 11.0 mol/g/h 
respectively.  Dividing through by the total amount adsorbed initially (see Table 3.6) we get 
apparent first-order rate constants 0.616 h
-1
, 0.00483 h
-1
, 0.629 h
-1
 and 0.337 h
-1
.  The result for 
SH-SBA is very small because A is much smaller than the total amount adsorbed. Release rates 
are in the same order as the release amounts, i.e., COOH-SBA > Ex-SBA > SH-SBA. For SH-
SBA and Ex-SBA samples, the bonding between host materials and guest drug molecules has no 
significant change, and thus R6G release rate from Ex-SBA is faster than that from SH-SBA 
because the binding in the former is weaker than that in the latter. 
The role of pore size on the R6G release of drug loaded samples was also investigated. After 
5 hours, the release amounts of R6G from carboxylic grafted samples approach the maximum, 
i.e., 14.4 mg/g for COOH-SBA sample and 1.76 mg/g COOH-MCM. Release amount from 
COOH-SBA is larger than that from COOH-MCM sample. The release percentage of R6G out of 
total amount loaded in the sample is 17.9% for COOH-SBA sample and 5.4% for COOH-MCM 
sample. It has the same order as the release amount, i.e., COOH-SBA >COOH-MCM. Release 
rate for COOH-MCM is 11.0 µmol/g/h, which is also less than that of COOH-SBA (50.8 
µmol/g/h). It is consistent with the release amounts order. Considering two samples have the 
same functional group, R6G molecule should have nearly same strength of attraction to the host 
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materials. So, the main reason for this difference should be due to the pore size difference. SBA 
has larger pore size than MCM, so it is easier for R6G molecules to release from channels. 
(A) 
 
 
 
(B) 
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Figure  3. 6  (A) Release percentage of R6G loaded Ex-SBA, SH-SBA and COOH-SBA 
materials over different time, (B) Release amount of R6G loaded Ex-SBA, SH-SBA and COOH-
SBA materials over different time, (C) Release percentage of R6G loaded Ex-COOH-SBA and 
COOH-MCM materials and (D) Release amount of R6G loaded Ex-COOH-SBA and COOH-
MCM materials over different time. 
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Table 3. 7  Release (mg/g material) of ibuprofen as function of time. 
Material 
t/h 
1 2.5 5 10.5 24 52.7 
Ex-SBA 0.143 0.135 0.143 0.1516 0.142 0.156 
SH-SBA 0.124 0.13 0.112 0.1452 0.142 0.136 
COOH-SBA 0.133 0.132 0.131 0.14 0.144 0.149 
MCM-COOH 0.0664 0.0723 0.07 0.0814 0.0864 0.0963 
 
 
 
 
Table 3. 8  Release per cent of ibuprofen as function of time.  
Material 
t/h 
1 2.5 5 10.5 24 52.7 
Ex-SBA 0.0407 0.0385 0.0407 0.0432 0.0405 0.0444 
SH-SBA 0.0623 0.0653 0.0563 0.0730 0.0714 0.0683 
COOH-SBA 0.0739 0.0733 0.0728 0.0778 0.0800 0.0828 
MCM-COOH 0.0531 0.0578 0.0560 0.0651 0.0691 0.0770 
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Figure  3. 7 (A) Release percentage of ibuprofen loaded Ex-SBA, SH-SBA and COOH-SBA 
materials over different time, (B) Release amount of ibuprofen loaded Ex-SBA, SH-SBA and 
COOH-SBA materials over different time, (C) Release percentage of ibuprofen loaded Ex-
COOH-SBA and COOH-MCM materials and (D) Release amount of ibuprofen loaded Ex-
COOH-SBA and COOH-MCM materials over different time. 
 
 
The release data of ibuprofen from SBA functionalized samples are summarized in Table 
3.7 and Table 3.8 and plotted in Figure 3.7.  After 2.5 hours, the release amount of ibuprofen 
from three SBA samples approaches the maximum.  Figure 3.7 also shows the best fits to 
Equation 5, which give A, maximum released, as 0.146 mg/g for Ex-SBA, 0.133 mg/g for SH-
SBA, and 0.140 mg/g for COOH-SBA sample. Table 3.9 gives other quantities calculated from 
the fits. The release amount is almost the same, i.e., Ex-SBA≈SH-SBA≈COOH-SBA. The 
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release percentage of ibuprofen out of total amount loaded in the SBA samples is 0.041% for Ex-
SBA, 0.067% for SH-SBA, and 0.077% for COOH-SBA sample. It decreases in the order 
COOH-SBA > SH-SBA > Ex-SBA.  From A and the amount of ibuprofen adsorbed originally, 
we calculate Keq, the equilibrium constant for adsorption. 
Table 3. 9 A and Q values for ibuprofen release test  
 
Material Ex-SBA SH-SBA COOH-SBA COOH-MCM 
A (mg/g material) 0.146 0.133 0.140 0.0820 
Q (see equation 5) 4.00 2.67 3.00 1.53 
Total adsorbed (mg/g) 351 199 180 125 
f = fraction released 0.000416 0.000668 0.000778 0.000656 
Keq for adsorption 2403 1495 1285 1523 
 
Table 3.9 shows that very large values are obtained, because the fraction released is always 
very small.  These values are so large that the explanation, that most of the ibuprofen is 
unavailable for desorption because of changes occurring during the 48-hour drying and storage 
process between the adsorption and desorption is not correct.  We consider the other explanation, 
saturation of binding sites.  The theory is essentially the Langmuir theory and has been used for 
the drug adsorption study
19
. 
Suppose the adsorbent can be saturated, i.e. there are only a limited number of adsorption 
sites.  The rate of adsorption is proportional to the number of empty sites.  Let c = concentration 
of adsorbate in solution. Let n = concentration of adsorbate adsorbed by the material.  We keep 
everything in concentration units; n may be calculated as the moles adsorbed divided by the 
volume of solution. Let m be the maximum concentration of adsorbate that can be adsorbed.  The 
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rate of adsorption, in concentration per unit time, is kac(mn) and the rate of desorption is kdn.  
At equilibrium, 
   
n
n)c(m
a
d 
k
k
     [7] 
so, defining the equilibrium constant K as ka/kd, we show 
   n = 
Kc1
Kmc

                  [8] 
For small c, n is about Kmc, but, for large c, n approaches m (saturation).   
There are two unknown constants, K and m, requiring two measurements.  Suppose that in 
an adsorption measurement on a drug we get equilibrium with solution concentration ca and 
adsorbed concentration na, and then in a desorption measurement we get equilibrium with 
solution concentration cd and adsorbed concentration nd.  Then equation 7 shows 
   m = nand
daad
ad
ncnc
cc


     [8] 
Also,                             K = 
da
aadd )/()/(
nn
cncn


    [9] Table 3.10 and 
Table 3.11 shows the results of calculations for R6G and ibuprofen using equation [8]. 
 
 
 
Table 3. 10 results of calculations for R6G 
Material ca (M) na (M) cd (M) nd (M) m (M) K (M

) 
Ex-SBA 654 356 45.7 300.3 350 0.132 
SH-SBA 338 662 2.5 659.5 662 104.7 
COOH-SBA 193 817 144 673 2201 0.003 
COOH-MCM 674 326 17.6 308.4 326 0.968 
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Table 3. 11 results of calculations for ibuprofen 
Material ca 
(mg/mL) 
na 
(mg/mL) 
cd 
(mg/mL) 
nd 
(mg/mL) 
m 
(mg/mL) 
K ×10
5 
(mL/mg) 
Ex-SBA 6.49 3.51 0.00146 3.51 3.51 16.5 
SH-SBA 8.01 1.99 0.00133 1.99 1.99 11.2 
COOH-SBA 8.2 1.8 0.0014 1.80 1.80 9.2 
COOH-MCM 8.75 1.25 0.00082 1.25 1.25 18.6 
 
From definition of the equilibrium constant K as ka/kd, we can know the smaller K stands for 
larger release capacity. For R6G release data in Table 3.10, the equilibrium constant K for 
COOH-SBA is 0.003, 0.132 for Ex-SBA and 104.7 for SH-SBA. The release capacity is in the 
order of COOH-SBA > Ex-SBA > SH-SBA.  For ibuprofen release data in Table 3.11, the 
equilibrium constant K for COOH-SBA is 9.2×10
5
, 16.5 ×10
5
for Ex-SBA and 11.2×10
5
 for SH-
SBA. The release capacity is in the order of COOH-SBA > SH-SBA >Ex-SBA. 
       The pore size effect on ibuprofen release was also investigated. After 2.5 h release, the 
release amount of ibuprofen from carboxylic grafted samples approach the maximum, i.e., 0.140 
mg/g for COOH-SBA sample and 0.0820 mg/g COOH-MCM. Release amount decreases in the 
order COOH-SBA >COOH-MCM.  The release percentage of ibuprofen of total amount loaded 
in the samples is 0.077% for COOH-SBA sample and 0.0656% for COOH-MCM sample which 
has same order as the release amount, i.e., COOH-SBA >COOH-MCM. Release rate for COOH-
MCM is 0.0010 mg/g
-1
/h
-1
 and it is also less than that of COOH-SBA. Considering both have the 
same functional group, the main reason should be the pore size as we discussed above. SBA has 
big pore size and it is easy for ibuprofen to come out of the mesoporous pores. 
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After we fitted the release curve, the release rate of ibuprofen from each sample was 
calculated. It is 0.00231mg/g/h for COOH-SBA, 0.00165 mg/g/h for EX-SBA and 0.00178 
mg/g/h for SH-SBA. Release rate is consistent with the release percentage order. This can be 
easily understood from strength of interaction between grafted functional group and ibuprofen 
molecule. The sample which has weaker binding with the ibuprofen molecule will have more 
release amount.  
3.3 Conclusion 
 
TGA and UV-Vis were conducted to characterize the loading and release of the drug. For 
R6G loaded samples, it was found that R6G load percent decreases in the order of COOH-SBA> 
SH-SBA >Ex-SBA. For ibuprofen loaded samples, it showed that the ibuprofen adsorption 
amount decrease after –SH and –COOH group modification which is completely different from 
R6G adsorption case. The adsorption amount of ibuprofen decreases in the order Ex-SBA > SH-
SBA > COOH-SBA.  After the first 5 h, the release amount of  R6G from three SBA samples all 
approaches the maximum,  Release amount decreases in the order COOH-SBA > Ex-SBA > SH-
SBA. The R6G release percentage out of total amount loaded in the SBA samples and release 
rate has the same order as the release amount order, i.e., COOH-SBA > Ex-SBA > SH-SBA, 
which is different from order of adsorption amount indicated above. It indicates that sample with 
larger adsorption amount doesn’t necessarily have larger release amount or larger release 
percentage than sample with less adsorption amount. 
Release amount from COOH-SBA is larger than that from COOH-MCM sample.  The 
release percentage of R6G out of total amount loaded in the sample and release rate has the same 
order as the release amount, i.e., COOH-SBA >COOH-MCM. Considering two samples have the 
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same functional group, R6G molecule should have nearly same strength of attraction to the host 
materials. So, the main reason for this difference should be due to the pore size difference. 
For ibuprofen loaded samples, the release amount of ibuprofen from three SBA samples 
reach the maximum after release in 2.5 hours. Release amount is almost same, i.e., Ex-SBA≈SH-
SBA≈COOH-SBA.  The release percentage of ibuprofen out of total amount loaded in the SBA 
samples and release rate decreases in the order COOH-SBA > SH-SBA > Ex-SBA.  However, 
the adsorption amount decrease in the order Ex-SBA > SH-SBA > COOH-SBA which is exactly 
opposite to the release order. This can be easily understood from strength of interaction between 
grafted functional group and ibuprofen molecule. The sample which has weaker binding with the 
ibuprofen molecule will have more release amount. The pore size effect on ibuprofen release was 
also conducted. After 2.5 h release, the release amount of ibuprofen from carboxylic grafted 
samples approaches the maximum and it decreases in the order of COOH-SBA >COOH-MCM. 
The release percentage of ibuprofen out of total amount loaded in the samples and release rate 
has same order as the release amount, i.e., COOH-SBA >COOH-MCM. Considering with the 
same functional group, the main reason should be the pore size as we discussed above. SBA has 
big pore size and it is easy for ibuprofen to come out of the mesoporous pores. This is consistent 
with the ibuprofen adsorption result for the two samples. 
3.4 Experiment Section 
3.4.1 Materials and reagents 
 
Tetraethylorthosilicate (TEOS), cetyltrimethylammonium bromide (CTAB), and poly 
(ethylene oxide)-block-poly (butylene oxide)-block-poly (ethylene oxide) (P123, EO20PO70EO20) 
were purchased from Sigma-Aldrich, 3-(trimethoxysilyl)-propionitrile (95%, Aldrich), 3--
mercaptopropyltrimethoxysilane (MPTS), sulfuric acid (H2SO4, 98%, SCR) 
111 
 
3.4.2 Synthesis of SBA materials 
 
SBA-15 was synthesized as reported by using P123 in acidic solution as a template.
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Usually, a solution of EO20PO70EO20 : 2 M HCl : tetraethoxysilane (TEOS) : H2O = 2 : 60 : 4.25 : 
15 (mass ratio) was stirred at 40 °C for 20 h, and then aged at 80 °C for another 24 h in the oven. 
The solution was then filtered, and the solid was washed with a large amount of water and dried 
to get “as-synthesized” SBA-15.  The surfactant was extracted by stirring 1g of above sample in 
300 mL ethanol and stirred at 50°C for 24 h. The resulting material was filtered and washed 
again with copious amount of water until it became neutral (checked with pH paper), and then 
washed with 500 mL ethanol and then 1000 mL distilled water and last 300 mL ethanol again. 
Dry the sample in the air and get extracted SBA-15. 
3.4.3  Synthesis of carboxylic acid functionalized-MCM-41 
 
The extracted MCM-41 was grafted with 3-(trimethoxysilyl)- propionitrile by stirring 400 
mg MCM-41 with 2.92 mmol of 3-(trimethoxysilyl)- propionitrile in 500 mL toluene for 6 h at 
80°C. The samples were then washed with copious amount of ethanol and let to dry under 
ambient condition resulting propionitrile functionalized MCM-41 sample, denoted as CN-
MCM41. Then, the above sample was hydrolyzed to get carboxylic modified MCM-41. Briefly, 
400 mg CN-MCM41 was mixed with 50 mL 48% H2SO4 solution and stirred at 95°C for 24 h to 
get carboxylic functionalized-MCM-41, referred as COOH-MCM-41.Then, the resulting 
material was filtered and washed again with copious amount of water until it became neutral 
(checked with pH paper), and then washed with 500ml ethanol and dried in the air. 
3.4.4  Synthesis of carboxylic acid functionalized SBA-15 
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The extracted SBA-15 was grafted with 3-(trimethoxysilyl)- propionitrile by stirring 400 mg 
SBA-15 with 2.92 mmol of 3-(trimethoxysilyl)- propionitrile in 500 mL toluene for 6 h at 80°C. 
The samples were then washed with copious amount of ethanol and let to dry under ambient 
condition resulting propionitrile functionalized SBA-15 sample, denoted as CN- SBA-15. Then, 
the above sample was hydrolyzed to get carboxylic modified SBA-15. Briefly, 400 mg CN-SBA-
15 was mixed with 50 mL 48% H2SO4 solution and stirred at 95°C for 24 h to get carboxylic 
functionalized- SBA-15, referred as COOH-SBA-15.Then, the resulting material was filtered and 
washed again with copious amount of water until it became neutral (checked with pH paper), and 
then washed with 500 ml ethanol and dried in the air. 
3.4.5  Synthesis of 3-mercaptopropyl-functionalized SBA-15 
 
The extracted SBA-15 was grafted with 3-mercaptopropyltrimethoxysilane (MPTS) by 
stirring 400 mg SBA-15 with 2.92 mmol of 3-mercaptopropyltrimethoxysilane (MPTS) in 500 
mL toluene for 6 h at 80°C. The samples were then filtered and washed with copious amount of 
ethanol, and let to dry under ambient condition resulting 3-mercaptopropyl functionalized SBA-
15 sample, denoted as SH-SBA-15. 
3.4.6  Adsorption of R6G and ibuprofen  
 
1000µM solution of R6G was prepared by dissolving R6G powder in distilled water  and 
10mg/ml solution of ibuprofen was prepared by dissolving ibuprofen powder in hexane. The 
R6G solution was covered with aluminum foil to avoiding light and ibuprofen solution was 
sealed in container in case of evaporation. For R6G adsorption, we took100 mg nanomaterials 
and mixed them with 10ml 1000µM solution of R6G at room temperature. The solution was 
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stirred for 5 minutes and then kept at static condition for 48h to establish equilibrium. For 
ibuprofen adsorption, we took100 mg nanomaterials and mixed them with 10ml 10mg/ml 
solution of ibuprofen at room temperature. The solution was sealed in the container and stirred 
for 5 minutes and then keep at static condition for 48h. Then the solutions were centrifuged in 
small tube for 30min and supernatant were taken to be monitored by UV-Vis. When tested under 
UV-Vis, the R6G supernatant was diluted 100 times and tested at 534 nm, and the supernatant of 
ibuprofen was diluted 20 times in a quartz cuvette and test at 264nm. From Lambert–Beer law, 
we calculated the adsorption amounts of the drugs. 
3.4.7  Release of R6G and ibuprofen  
 
For R6G release study,  we took 100 mg functionalized samples  and mixed with 10 ml  R6G 
water solution of 1mM at static condition for 48h. For ibuprofen release study, we took 100 mg 
functionalized samples and mixed with 10ml ibuprofen hexane solution  of 10mg/ml at static 
condition for 48h. After all functionalized samples were loaded with ibuprofen or R6G, samples 
were filtered and dried in oven overnight for release study. For the release study, we mixed 100 
mg functionalized samples loaded with ibuprofen or R6G with 40 ml SBF solution and stir 
constantly at 37 °C.  At various time intervals, we took 1.5ml solution into 1.9ml centrifuge tube 
to centrifuge for 30min before test UV-Vis. At each test, refill 1.5 ml fresh SBF to the release 
system and also put the samples left in each test solution to the release system, which make sure 
the samples for release stay same. 
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CHAPTER 4 ACCELERATED OXIDATION OF EPINEPHRINE BY 
SILICA NANOPARTICLES 
4.1 Introduction  
 
Catecholamines are biogenic amines responsibe for the acute stress response perceived by 
mammals upon unexpected stimuli coming from either external or internal surroundings.
1, 2
 In 
the view of chemistry, they are hormones and can be bio-synthesized from tyrosine and 
phenylalanine via hydroxylation to produce, among others, dopamine, norepinephrine and 
epinephrine.
3
 Among them, epinephrine (Figure 4.1) is the most potent agonist to adrenergic 
receptors in a various cells.
4-7
 Epinephrine will transmit neuronal signals to G-protein coupled 
receptors on the cell membrane once bound and a cascade of intracellular enzymatic reactions 
occur. As a result, much cyclic adenosine monophosphates are produced to activate glycogen 
phosphorylases which speed up the glycogenolysis to liberate glucoses into the bloodstream.
5-7
 
The resulting sudden energy burst will stimulates the body to make to fight or flight.  
   High level of epinephrine due to the frequent alternation of stress and depression can put our 
lives under the danger of tumorigenesis and cardiac dysfunction.
8, 9
 In addition, it is reported that 
this hormone could sabotage cancer threapy by inactivating the pro-apoptotic proteins.
10
 Thus, 
the controll of epinephrine production becomes necessary to either keep a normal physical 
condition or reinforce cancer treatment.   
 
Figure 4. 1 Structure of epinephrine molecule 
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 As a neurotransmitter, the function of epinephrine can be aborted if it is oxidized. But the 
autoxidation of epinephrine is very slow under the physiological conditions (pH=7.4). The 
oxidation process produces O2
- 
and H2O2 as intermediates and adrenochrome.
11,12
 Epinephrine 
oxidation involves a cyclization of the quinone moiety in the presence of superoxides.
13
 This step 
help to produce more reactive oxygen species and appears even more dominant at a higher pH 
condition.
13
 ∙O2
-
 reacts with H2O2 at neutral or basic condition to give ∙OH (+ O2 + OH
-
), which 
may be the active species in epinephrine oxidation.
 
In acidic solutions, ∙O2
-
 becomes HO2∙ which 
reacts with H2O2 to give ∙OH + O2 + H2O.
14
 Many enzymes, such as catechol oxidase and amine 
oxidase can catalyze the oxidation reaction of catecholamines and many other organic and 
inorganic materials.
15, 16
  
 In this dissertation, we investigated the accelerated oxidation of epinephrine in the 
presence of two MSN, SBA-15 and MCM-41. In order to emphasize the effect of mesoporous 
structure on the oxidative reaction, silica microspheres (SMS) were also tested in this study as a 
control.  
It was reported that oxidative stress and free radical-mediated lipid peroxidation may have a 
crucial role in various diseased states 
21-26
. To prevent and treat such diseases which relates to 
oxygen species, lots of study on antioxidants have been carried out. Some biologically important 
reactive oxygen species include the superoxide radical, the hydroxyl radical, peroxyl radical, 
singlet oxygen, and hydrogen peroxide. Caffeine (1,3,7-trimethylxanthine) is a ingredient that 
can be found  in a great amount of beverages such as tea, coffee, cola and food containing 
chocolate 
27,28
. And it was also reported as a scavenger of the hydroxyl radical at millimolar 
concentrations in the study of electron spin resonance (ESR) spin trapping 
29
. So, we also studied 
the epinephrine oxidation in the presence of caffeine. Antioxidant effects of caffeine and its 
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metabolites were also evaluated by the epinephrine oxidation rate. Same experiment was also 
investigated with its isomer, isocaffeine. 
4.2 Results and Discussion 
4.2.1 Characterizations of nanoparticles 
4.2.1.1 Transmission Electron Microscopy (TEM) 
 
The as-synthesized MCM-41 or SBA-15 was calcined to remove the template and result in 
ordered MCM-41 and SBA-15 nanoparticles. The transmission electron microscopy (TEM) 
images (Figure 4.2 A-B) indicate that SBA-15 particles are of irregular shape of different sizes 
and MCM-41 particles and silica spheres are of rather regular spheres. 
(A) 
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(B) 
C) 
 
Figure 4. 2  Transmission Electron Micrographs of (A) calcined SBA-15, (B) calcined MCM-
41and (C) silica nanospheres. 
 
 
4.2.1.2  Nitrogen Gas Adsorption (BET) 
 
 
The BET gas adsorption-desorption measurements were done with Micromeritics Tristar 
3000 volumetric adsorption analyzer for these two kinds of MSN after degassing the samples at 
160 °C for 12h, and both of the gas adsorption showed Type IV isotherms with steep capillary 
condensation steps (Figure 4.3).  This is indicative of the presence of mesoporous structure in 
these materials with large surface areas. BET surface area of MCM-41 was 1143 m
2
/g. Porosity 
by the Barrett-Joyner-Halenda (BJH) method shows a 28.4 Å average pore diameter and 
cumulative pore volume is 0.91cm³/g. For SBA-15 particles, the surface area is 883m
2
/g, the 
average pore width is 63.8 Å and the cumulative pore volume is 1.10cm
3
/g. These results are 
summarized in Table 4.1. Thus, compared to SBA-15, MCM-41 has a bigger surface area but 
smaller pore volume and width. Spherical silica nanoparticles were synthesized by following the 
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procedure stated in the Experimental Section. By adjustment of ammonia concentrations, quite 
symmetrical silica spheres of around 300 nm in diameter was synthesized (Figure 4.2 C). The 
BET gas adsorption-desorption measurements showed a surface area of 11 m
2
/g. Such a small 
surface indicates SMS nanopaticles are non-porous which correspond to their solid-cored 
structure.  
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Figure 4. 3  (A) Nitrogen gas adsorption (blue) and desorption (pink) isotherm of calcined 
MCM-41 (diamonds), SBA-15 (triangles) and silica spheres (circles). (B) BJH pore size 
distribution of calcined MCM-41 (diamonds) and SBA-15 (squares) mesoporous silica 
nanomaterials. 
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Table 4. 1 Characteristics of silica nanoparticles. Surface area, pore volume and average pore 
width are measured for three different nanomaterials as indicated.  
 Type of particles Surface area, m
2
/g  Pore volume, cm³/g BJH pore width, Å 
MCM 1143 0.91 28.4 
SBA 883 1.10 63.8 
Silica sphere 11 - - 
 
4.2.1.3  UV-Vis Spectra of Epinephrine 
 
 
Firstly we investigate the UV-Vis spectrophotometry of epinephrine solutions. Epinephrine 
of various concentrations from 20 to 240 M in dH2O were prepared and immediately scanned at 
wavelengths from 800 to 200 nm. Results are shown in Figure 4.4 A.  There are two absorbance 
peaks in the spectrum with one peak at ~200 nm and the other at ~280 nm. Moreover, one 
absorbance shoulder was evident lying in the wavelengths between 210-230 nm. All the spectra 
depend on epinephrine concentration. For higher concentration of epinephrine, the peak intensity 
is strong while the intensity of peak for lower concentration of epinephrine is weaker. To 
compare and evaluate the change of absorbance over epinephrine, we calculate the sum of 
intensities for a number of wavelengths rather than absorbance at a single wavelength because 
different concentration of epinephrine result a little shift of the absorbance peak. In Figure 4.4 B, 
the sum of intensities for the band of 195-205 nm, 210-230 nm, and 270-290 nm are plotted as a 
function of epinephrine concentration.  
For the band of 195-205 nm, the sum of intensities (diamonds) first increases with the 
addition of epinephrine, but then reaches a plateau. The later independency of the integrated 
intensities on the concentrations of epinephrine is associated with an instrumental limitation. So 
we fit the sum of intensities of the band 195-205 nm as a two-line function of [epinephrine] (i.e., 
[EP]): S195-205 (the sum of intensities) = 0.250 [EP] (when [EP] < 129.6 M) and S195-205 = 32.4 
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(when [EP] > 129.6 M).  But the sum intensities for band 210-230 nm and 270-290 nm (squares 
and triangles) increased with the [EP] over the whole concentration range. The fitting of the sum 
of intensities for each individual band vs. [EP] into a linear function passing through zero gives: 
for the 210-230 nm band, S210-230 = 0.121 [EP] (r
2
= 0.979); and for the 270-290 nm band, S270-290 
= 0.044 [EP] (r
2
= 0.983), respectively. Therefore, except the instrumental limitation, the 
integrated intensities for each band demonstrated proportionality to [EP]. Thus, the ratio between 
any two of three variables (S195-205, S210-230, and S270-290) in a spectrum remains unchanged, so that 
these three absorbances very likely result from the same epinephrine species, which prevails in 
the freshly made epinephrine solutions. 
 Extensive studies on transient free radical forms of catecholamines have enabled a good 
understanding of in situ oxidation of epinephrine to adrenochrome through a sequential one-
electron loss, although it is possible that other intermediate steps also exist.
11-13,30-32
 Instead of 
reacting directly with O2 dissolved in solutions, epinephrine is much more easy to react with the 
hydroxyl radical “·OH” which is resulted from the reaction between O2- and H2O2 and then 
epinephrine converts to o-semiquinone radical.
11-16
 Under neutral or acidic conditions, the 
concentration of O
2-
 and ·OH produced from reaction between O
2-
 and H2O2 is very low, so 
oxidation rate of epinephrine is low correspondingly.  On the contrary, O
2-
 can be formed 
quickly in basic condition, and then reduced to H2O2 rapidly which can further reacts with 
remaining O
2-
 to produce ·OH. Furthermore, in basic medium the oxidative product 
adrenochromes are not stable because they are liable to interact with OH-. These processes result 
a rapid oxidation of epinephrine at elevated pH. It has been reported that the rate of epinephrine 
oxidation at pH = 8 is almost four times higher than that at pH = 4.33 
124 
 
 
 
Figure 4. 4  (A) UV absorption spectrum for epinephrine for concentrations of 20-200 M.  (B) 
Band intensities for epinephrine as functions of epinephrine concentration with fits.   = 195-
205 nm,  = 210-290 nm,   = 270-290 nm.  Linear fits are given for the first two, whereas the 
third is fit to two intersecting lines.    
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(B) 
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(C) 
 
 
 
Figure 4. 5  Absorbance of adrenochrome (product of epinephrine oxidation) at 480 nm as a 
function of time.  The different plots correspond to different pH of the original epinephrine 
solutions.  The slopes of the plots give the rate of epinephrine oxidation.  Figure 4.5 A: Empty 
circles = pH 1, Filled triangles = pH 2, Empty triangles = pH 3, Filled diamonds = pH 4, Filled 
circles = pH 5, Empty squares = pH 6.   
Figure 4.5 B: Empty squares = pH 6, Filled triangles = pH 7, Empty triangles = pH 8, Empty 
circles = pH 9.   
Figure 4.5 C:  Empty circles = pH 9, Filled squares = pH 10, Empty triangles = pH 11, Filled 
diamonds = pH 12.  
 
 
So we investigate the effect of pH on the epinephrine oxidation rates by monitoring the 
absorbance of the adrenochrome produced in the solution at 480 nm over time.
13, 34 
When 
investigating the effect of pH on epinephrine oxidation reaction, all water solutions of different 
pH values were prepared with two times higher [H
+
] by adding NaOH or HCl, and then mixed 
with the same volume of 250 M epinephrine immediately right before test. Thus various 
epinephrine solutions of 125M in dH2O with different pH (pH = 1-12) was prepared. The same 
mixture without addition of epinephrine was tested to confirm the desired starting pH values. 
The pH can be adjusted by adding HCl for acidic conditions and NaOH for basic conditions. 
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Absorbance readings were taken for every 5 s for 30 min and the results are shown in Figure 4.5 
and the absorbance is expected to increase with the time because there are gonna more 
adrenochrome being produced with the oxidation of epinephrine going on. The negative value of 
in the graphs in Figure 4.5 is due to instrument limitation when the adsorbance is very low. At 
acidic conditions, the production of adrenochrome is minimal (Figures 4.5 A and 4.5 B). The 
gradual decrease in intensity, which appears similar in most of these conditions, may be due to 
the drift in the instrument. However, the decrease over the first few minutes likely represents an 
induction time, required for the formation of ·OH to oxidize the epinephrine. For a quantitative 
measure of the epinephrine oxidation, we obtain linear fits to only the data for t  200s. This 
gives the slopes (×10
-7
 s
-1
): -3.12 + 0.07 (r
2 
= 0.85), -4.85 + 0.11 (r
2 
= 0.87), 0.37 + 0.08 (r
2 
= 
0.07), -0.88 + 0.07 (r
2 
= 0.36), -0.13 + 0.09 (r
2 
= 0.01), and 3.65 + 0.13 (r
2 
= 0.72) for solutions at 
pH = 1, 2, 3, 4, 5 and 6, respectively.  
At pH = 7-10 (Figures 4.5 B and 4.5 C), the absorbance at 480 nm first declines a little 
bit, but then increases linearly with time. (Note the difference in scale between Figures 4.5 A, 4.5 
B, and 4.5 C). As before, the initial drop could be due to an induction time required to generate 
active oxygen radicals. These plots were fit to V-shaped functions (the overall r
2
 values are all 
greater than 0.98); in all cases, the bottom of the V was at ~220 s, suggesting a certain fixed time 
is required for the fast oxidization of epinephrine to begin under these neutral or weakly alkaline 
conditions. The slopes after the minimum, when [adrenochrome] increases linearly with time, 
were (×10
-6
 s
-1
) are 1.20, 3.68, 3.51, and 2.53 for the solutions of pH = 7, 8, 9 and 10, 
representing an order-of-magnitude increase in rate over the slopes at acidic conditions.  
In solution with pH = 11 (Figure 4.5 C), the production of adrenochrome drops off 
initially, and then quickly increases, showing the rapid oxidization of epinephrine. Later it 
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declines again, probably due to the instability of high concentrations of adrenochrome in this 
solution. Further evidence for the destruction of adrenochrome is the shape of the plot for pH 11. 
Excluding the first decreasing part before oxidation occurs, we fit the increasing part of the data 
to a cubic, i.e., [Intensity] = -9.6×10
-9 
t
2 
+ 2.2×10
-5 
t
 
-3.4×10
-3
 (75 < t < 1030 s, r
2 
=0.99). The rate 
of adrenochrome production is then equal to (2.2 ×10
-5 
-1.9 ×10
-8 
t) s
-1
, much higher than those at 
smaller pH. At pH = 12, the oxidation of epinephrine starts immediately. After a sharp increase, 
the production of adrenochrome slows down abruptly, so that the concentration almost levels off. 
By fitting these data to a two-line function, we get the slope for the rapid oxidation 3.3 ×10
-5 
and 
the slope for the slow one 9.9 ×10
-7
 (overall r
2
 value = 0.95). The apparent “slow oxidation” is 
really a net rate of production of adrenochrome, i.e., its rate of production minus that of 
destruction. These results show that the oxidation of epinephrine is highly pH-dependent, and the 
rate of adrenochrome production is clearly higher at higher pH.  
4.2.1.4 Effect of SBA-15, MCM-41 and silica sphere on epinephrine Oxidation 
 
 
In the following experiments we measure the rates of epinephrine oxidation in dH2O with or 
without silica nanoparticles. 10 mg/mL SBA-15, MCM-41 or silica spheres were individually 
dispersed in dH2O and sonicated until well suspended. Each suspension was then centrifuged, 
and the resulting supernatant was mixed with 125 M freshly prepared epinephrine solution and 
instantly collected for the spectroscopic scan. Our previous studies on drug adsorption by silica 
nanoparticles showed that centrifugations were not sufficient to remove all nanoparticles from 
the supernatant.
35
 Therefore, these experiments measure epinephrine oxidation in the presence of 
these silica nanoparticle residues.   
The results are shown in Figure 4.6. The absorbance at 480 nm was fit to a linear function 
of t in each case, the slope giving the rate of epinephrine oxidation. The different intercepts in 
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the beginning of oxidation reveal the “pseudo-adsorption” due to the scattering of 480-nm 
radiation from the nanoparticle residues; only the slopes are significant. In the absence of 
nanoparticles, epinephrine (solid curve) oxidizes to adrenochrome at a rate of (10.00 + 0.07) ×10
-
7
 s
-1
 (r
2 
=0.98). With particles present, the oxidation rate becomes (9.76 + 0.06) ×10
-7
 s
-1
 (r
2 
=0.99) 
for MCM-41 addition (long-dashed curve), (15.74 + 0.08) ×10
-7
 s
-1
 (r
2 
=0.99) for SBA-15 
addition (hatched curve), and (9.89 + 0.10) ×10
-7
 s
-1
 (r
2 
=0.96) for silica sphere addition (short-
dashed curve). Obviously, the presence of MCM-41 or silica spheres does not accelerate the 
oxidation, whereas SBA-15 exhibits an exceptional ability to enhance the oxidation rate of 
epinephrine to adrenochrome (by 57.4%), although all the oxidations proceed very slowly in 
dH2O. The same experiments done with no epinephrine show that the slopes of absorbance at 
480 nm vs. t (due to nanoparticles) are essentially zero for all nanoparticles (data not shown).  
 
 
Figure 4. 6  Absorbance at 480 nm due to adrenochrome as a function of time for epinephrine 
solutions without (solid line) and with silica nanoparticles.  Long-dashed line = addition of 
MCM-41, hatched line = addition of SBA-15, short-dashed line = addition of silica spheres. 
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We next examine the oxidation of epinephrine in PBS, with or without silica 
nanoparticles. The experiments were performed the same as the above, except dH2O was 
replaced with PBS solutions. Results are shown in Figure 4.7. With no nanoparticles added 
(hatched line), epinephrine oxidizes much more quickly in PBS than in dH2O. The absorbance 
due to the produced adrenochrome increases at a rate of 5.04×10
-5
 s
-1
, over 50 times higher than 
in dH2O. This enhancement of oxidation rate could be due to the weak acidity of dH2O (pH = 6), 
at which we have illustrated previously that oxidation occurs slower. Moreover, the higher ionic 
strength in PBS solutions (~ 0.15 M, as that in physiological condition) may contribute to this 
increased oxidation velocity as well. Later, the addition of silica spheres (short-dashed line) leads 
to a rate of oxidation of epinephrine to adrenochrome of 5.19×10
-5
 s
-1
, so there is no sign of silica 
spheres accelerating the oxidation in PBS. However, with either MCM-41 (solid line) or SBA-15 
(long-dashed line) nanoparticles present, the oxidation is clearly enhanced.  These curves are 
better fit by polynomials than straight lines, since the apparent rates decrease with time. The later 
reductions in the rate of production of adrenochrome reflect the instability of this product in 
these solutions. By fitting each absorbance vs. t in to a quadratic form, we have [Intensity] MCM = 
-1.42×10
-8 
t
2
+ 9.61×10
-5 
t
 
+ 8.16×10
-3
 (r
2 
>0.99) and [Intensity] SBA = -1.39×10
-8 
t
2
+ 8.60×10
-5 
t
 
+ 
1.68×10
-2
 (r
2 
>0.99). Thus, in the presence of MCM-41 and SBA-15, the oxidative reaction of 
epinephrine to adrenochrome occurs at a rate of (9.61×10
-5 
-2.84×10
-8 
t) s
-1 
and (8.60×10
-5 
-
2.78×10
-8 
t) s
-1
, respectively. The initial rates are 9.61×10
-5
 s
-1 
and 8.60×10
-5
 s
-1
, both higher than 
that for epinephrine oxidation in PBS with no nanoparticles. The same experiments were also 
done without epinephrine and the result shows that the slopes of absorbance at 480 nm vs. t in 
PBS (due to nanoparticles) are essentially zero. 
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To further investigate the accelerated oxidation of epinephrine by MSN in PBS and/or 
dH2O, we perform experiments in which dithionite is added into epinephrine solutions in 
different time sequences. Sodium dithionite (Na2S2O4) is well known to consume O2 molecules 
rapidly in aqueous solutions, producing bisulfate and bisulfite, where the reaction involves free 
radical intermediates, including ∙O2
-
.
36,37
 In the present experiments, dithionite was first 
dissolved in dH2O at a high concentration (1 M) and then diluted into dH2O or PBS solutions 
(final concentration [S2O4
2-
] = 500 M), either 5 min prior to, or simultaneously with, the 
addition of 125 M epinephrine. Results are shown in Figure 4.8. Time zero corresponds to the 
addition of epinephrine. In dH2O, dithionite added 5 min before (dotted curve) or at the same 
time as (long-dashed curve) the epinephrine addition prevents production of adrenochrome 
(which was low in any case). However, in PBS solutions, rapid oxidation of epinephrine occurs 
when epinephrine is added concurrently with dithionite (solid curve), whereas epinephrine is not 
oxidized if it is added 5 min after the dithionite addition. The addition of dithionite alone to 
either dH2O or PBS gives no rise in the absorbance at 480 nm (data not shown). 
Since 500 M dithionite can scavenge dissolved O2 in seconds and simultaneously 
generate radical intermediates like O2
-
,
36, 37
 this result confirms that, rather than O2 molecules, 
oxygen radicals are responsible for the rapid oxidation of epinephrine in a phosphate buffer 
environment. Concomitantly, it suggests that the accelerated epinephrine oxidations with MSN 
present in PBS are due to the accumulation of reactive oxygen species by the nanoparticles. 
Apparently, MCM-41 or SBA-15 silica nanoparticles, but not silica spheres, provide a hotbed for 
oxygen radicals. In dH2O the epinephrine oxidation is not accelerated by dithionite, even when it 
is added simultaneously with epinephrine. A possible explanation for this is that dithionite 
generates, in addition to oxygen radicals that should be able to execute the epinephrine oxidation, 
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HSO3
-
 and HSO4
-
 ions. In an unbuffered solution, these ions create an acidic environment which 
undermines the reaction. In fact, the measured pH of a 500 M dithionite solution in dH2O is 3.7 
+ 0.1.    
 
 
Figure 4. 7  Absorbance of adrenochrome at 480 nm as a function of time, from epinephrine 
solutions in PBS, with and without silica nanoparticles.  
 
 
Figure 4. 8  Absorbance of adrenochrome at 480 nm as a function of time, from solutions of 
dithionite + epinephrine.  Dotted curve = dH2O with dithionite added 5 min before epinephrine, 
long-dashed curve = dH2O with dithionite and epinephrine added simultaneously, short-dashed 
curve = PBS with dithionite added 5 minutes before epinephrine, solid curve = PBS with 
dithionite and epinephrine added simultaneously. 
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4.2.1.5  UV-Vis Spectra of Caffeine and Isocaffeine 
 
 The spectra of caffeine and isocaffeine solutions were first investigated using UV-Vis 
spectrophotometry. Different concentrations of both trimethylxanthines (0-120 M) in PBS were 
prepared and immediately scanned at wavelengths from 350 to 190 nm (no noticeable peaks 
appeared after 350 nm in the visible range). Results are shown in Figure 4.9. In each spectrum of 
caffeine, two absorbance peaks can be observed, one at ~205 nm and the other at ~273 nm. In 
addition, one absorbance shoulder was evident, in the wavelength region of 225-240 nm. All the 
spectra are concentration-dependent, showing the stronger intensity resulting from the higher 
concentration of caffeine. However, changing concentration also produced a small shift in the 
wavelength of the absorbance peak, which could be resulted from the instrumental limitations. 
Therefore, we here adopted an integrated absorbance over a band, i.e., the sum of intensities 
under a number of wavelengths, in replacement of the absorbance at a single wavelength. Shown 
by the inserted graph in Figure 4.9 A, the summed intensities for 200-205 nm (solid squares), 
225-235 nm (solid triangles), and 270-275 nm (empty squares) are plotted as functions of 
caffeine concentrations, respectively. For the 200-205 nm band, clearly, the sum of intensities 
increases with addition of caffeine, and we thereby fit the two variables into a linear function 
(solid line). That is, S200-205 (the sum of intensities in 200-205 nm band) = (0.131+0.004) [caf.] + 
(0.572+0.224) (r
2
= 0.996), where [caf.] stands for [caffeine]. Intercept turns out to be positive, 
although numerically this small intercept can be neglected when high [caf.] (e.g., 100 M) is 
used. Therefore, under circumstances where high concentration of caffeine is employed, 
proportionality still applies between S200-205 and [caf.]. For the 225-235 nm and 270-275 nm 
bands (empty squares and triangles, respectively), the integrated intensities both increased with 
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[caf.]. The fitting of the sum of intensities for each individual band vs. [caf.] into a linear 
function passing through zero gives: for the 225-235 nm band (dashed line), S225-235 = 
(0.055+0.000) [caf.] + (-0.046+0.022) (r
2
> 0.999); and for the 270-275 nm band (dotted line), 
S270-275 = (0.057+0.000) [caf.] + (-0.011+0.012) (r
2
> 0.999). Intercepts are both statistically zero. 
Obviously, both integrated intensities for each band demonstrated proportionality to [caf.]. In 
brief, at a relatively high concentration of caffeine, the ratio of any two of the three variables 
(S200-205, S225-235, and S270-275) remains nearly unchanged; thereby, these three absorbance ranges 
could result from the same caffeine derivatives, prevailing in the freshly made caffeine solutions. 
     Compared to the spectra of caffeine, those of isocaffeine displayed many a difference. First, 
the absorbance shoulder in caffeine spectra vanished; instead, an absorbance peak formed around 
239 nm. By adding together the intensities from 235 nm to 240 nm, we fit this sum (S235-240) into 
a linear function versus [isocaffeine] (i.e., [isocaf.]) and obtained: S235-240 = (0.055+0.002) 
[isocaf.] + (-0.034+0.097) (r
2
= 0.991) (dotted line as shown in the insert of Fig.4.9 B). 
Statistically, intercept was zero. Second, the long-wave band in previous caffeine spectra (~273 
nm) made a hypsochromic shift in isocaffeine solutions, about 5 nm downwards to the blue. As a 
result, peaks under ~ 268 nm were observed in isocaffeine spectra, and the sum of intensities 
covering 265 nm to 270 nm was therefore fit into a function of [isocaf.] (dashed line). The linear 
regression returns as S265-270 = (0.069+0.003) [isocaf.] + (-0.071+0.124) (r
2
= 0.991), where the 
intercept was basically zero. Third, the short-wave band including 200-205 nm stayed as it 
showed in caffeine aqueous solutions, but the corresponding intensities were clearly augmented. 
By fitting the sum of intensities versus [isocaf.] into a linear function (solid line), we got S200-205 
= (0.155+0.005) [isocaf.] + (0.753+0.231) (r
2
= 0.993). Here, intercept was positive, although a 
large value of [isocaf.] (> 100 M) would leave this number negligible. We noticed that the 
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slope was higher in S200-205 of isocaffeine than that of caffeine. That is, in PBS solutions, the 
isocaffeine owns a higher value of extinction coefficient than its isomer. All different 
characteristics existing between caffeine and isocaffeine underlined a structural variation, 
reflecting the effect of –CH3 position change on physicochemical properties of xanthine 
compounds. Be noted - the repeated occurrence of positive intercepts in the 200-205 nm range 
pointed out one possibility that the PBS solution containing no drug might may have a non-zero 
absorbance in this region, which was later proven true by scanning the spectra of PBS solution 
(results are not shown). However, with [caf.] or [isocaf.] ≥ 100M, The summed intensities from 
200-205 nm band, coming from the PBS solution,  is insignificant.  
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Figure 4. 9  UV-Vis Spectra of Caffeine and Isocaffeine 
 
4.2.1.6  Accelerated Oxidation of Caffeine and Isocaffeine by MSN 
 
 
In order to investigate the oxidation of caffeine and its isomer in aqueous solutions, using 
UV-Vis spectrometry, we first monitored the spectral density over time when dissolving 100μM 
isocaffeine or caffeines in PBS. As a result, there came no noticeable change in their absorbance 
spectra during 24 hours (results are not shown), suggesting either a very sluggish oxidation or an 
indistinguishable difference between isocaffeine, caffeine and their oxidized forms in absorbance 
spectra. Thereby, to visualize the oxidation of isocaffeine and caffeine in a much shortened 
timeframe or in a convenient manner, we examined the oxidation of epinephrine at 480 nm in the 
presence of silica nanoparticles, when isocaffeine or caffeine were added or kept clear. Because 
of the crucial role of hydroxyl radicals (OH·) produced inside the mesoporous channels in a 
phosphate-buffered environment in the accelerated oxidation of epinephrine by MSN, these 
hydroxyl radicals have been thought capable to induce the oxidation of caffeine. Therefore, once 
hydroxyl radicals are formed due to the presence of MSN in PBS, oxidation of caffeine may take 
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place which will compete with the oxidation of epinephrine. Thus, the expecting accelerated 
oxidation of epinephrine by MSN would be retarded. 10 mg/mL SBA-15 was dissolved in PBS 
solution and the precipitates of nanoparticles were removed by centrifugation, keeping 
supernatants for further use. Centrifugation was believed not sufficient to remove all 
nanoparticles in the solution, leaving residues of nanomaterials in the supernatant. Epinephrine 
of 125 μM was then added into such  BS solutions, further added with or without various 
concentrations of (iso) caffeine. Solutions were immediately collected for spectroscopic 
measurements and were monitored at 480 nm for 30 min with absorbance reading taken every 5 s. 
In the following experiments we measure the rates of epinephrine oxidation in PBS with or 
without silica nanoparticles. To study the caffeine and isocaffeine effect on oxidation rate, we 
also dissolve caffeine or isocaffeine of different concentration in epinephrine before mix with 
silica particles. 10 mg/mL SBA-15 or silica spheres were individually dispersed in 2×PBS and 
sonicated until well suspended. Each suspension was then centrifuged, and take 1ml resulting 
supernatant and  mix with 1ml 250 M freshly prepared epinephrine solution containing caffeine 
or isocaffeine of different concentration (0.5mM, 1.0mM, 2.0mM, 4mM) and instantly collected 
for the spectroscopic scan. So, in the test solution, the epinephrine concentration is 125M with 
caffeine or isocaffeine of 0.25mM, 0.5mM, 1.0mM, 2.0mM and 1×PBS. Our previous studies on 
drug adsorption by silica nanoparticles showed that centrifugations were not sufficient to remove 
all nanoparticles from the supernatant.
33
 Therefore, these experiments measure epinephrine 
oxidation in the presence of these silica nanoparticle residues.  The results are shown in the 
Figures below. The absorbance at 480 nm was fit to a linear function of t in each case, the slope 
giving the rate of epinephrine oxidation. In the absence of nanoparticles, epinephrine oxidizes to 
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adrenochrome at a rate of (7.49 + 0.008) ×10
-5
 s
-1
 (r
2
 =0.99). With SBA-15 present, the oxidation 
rate increases to (8.01 +0.005) ×10
-5
 s
-1
 (r
2
 =0.99). 
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Figure 4. 10  From top to down: Epinephrine SBA caffeine(2mM), Epinephrine SBA 
caffeine(0.25mM), Epinephrine, Epinephrine SBA caffeine(0.5mM), Epinephrine SBA 
caffeine(0mM), Epinephrine SBA caffeine(1mM) 
 
Figure 4.10 shows the result of a series of test with caffeine of various concentrations. The 
oxidation rate decreases with the increase of caffeine concentration. With the caffeine 
concentration increasing from 0.25mM to 2mM, the oxidation rate reduced as the following: 
(8.15 + 0.008)×10
-5
 s
-1
 (r
2
 =0.99), (7.53 + 0.008)×10
-5
 s
-1
 (r
2
 =0.99), (7.08 + 0.008)×10-5 s
-1
 (r
2
 
=0.99), (6.18 + 0.008)×10
-5
 s
-1
 (r
2
 =0.99). In general, the oxidation rate decreases after addition 
of caffeine. Also, oxidation rate decreases more when the caffeine concentration is higher.   
 The result of same test with isocaffeine was plotted in Figure 4.11. In the absence of silica 
nanoparticle, oxidation rate is (8.57+0.01) ×10
-5
 s
-1
 (r
2
 =0.99). After adding SBA particle, it 
increase to (9.02+0.02)×10
-5
 s
-1
 (r
2
 =0.99); After addition of isocaffeine, with the concentration 
changing from 0.25mM to 2mM, the oxidation rate decreased from to (9.45+0.01)×10
-5
s
-
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1
(r
2
=0.99), (9.15+0.009)×10
-5
s
-1
 (r
2
=0.99), (8.49+0.009)×10
-5
 s
-1
 (r
2
=0.99), (6.73+0.008)×10
-5
 s
-1
 
(r
2
 =0.99). It has same effect as caffeine does. 
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Figure 4. 11  From top to down: Epinephrine SBA isocaffeine(0.25mM), Epinephrine SBA 
isocaffeine(0.5mM), Epinephrine SBA isocaffeine(0mM), Epinephrine SBA isocaffeine(1mM), 
Epinephrine, Epinephrine SBA isocaffeine(2mM) 
 
Replacing SBA-15 with silica sphere, a series of same experiment was also conducted on the 
oxidation of epinephrine. As showed in Figure 4.12, in the absence of nanoparticles, epinephrine 
oxidizes to adrenochrome at a rate of (8.23 + 0.02) ×10
-5
 s
-1
 (r
2
 =0.99). With particles present, 
the oxidation rate becomes (8.68 +0.01) ×10
-5
 s
-1
 (r
2
 =0.99), there is a little increase though not a 
big change. With the addition of caffeine of different concentration, the oxidation rate decreases 
with the concentration increase. Corresponding concentration from 0.25mM to 2mM, the 
oxidation rate are (9.45 + 0.02) ×10
-5
 s
-1
 (r
2
 =0.99), (8.95 + 0.009) ×10
-5
 s
-1
 (r
2
 =0.99), (8.69 + 
0.008) ×10
-5
 s
-1
 (r
2
 =0.99), (8.59 + 0.006)×10
-5
 s
-1
 (r
2
 =0.99), respectively.  
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Figure 4. 12  From top to down: Epinephrine Si caffeine(2mM), Epinephrine Si 
caffeine(0.25mM), Epinephrine Si caffeine(0.5mM), Epinephrine Si caffeine(1mM), Epinephrine 
Si caffeine(0mM), Epinephrine 
 
After addition of isocaffeine, with the concentration of isocaffeine changing from 0.25mM to 
2mM, the oxidation rate changes to (9.02 + 0.02)×10
-5
 s
-1
 (r
2
 =0.99), (8.88 + 0.02)×10
-5
 s
-1
 (r
2
 
=0.99), (8.21 + 0.02)×10
-5
 s
-1
 (r
2
 =0.99), (7.38 + 0.02)×10
-5
 s
-1
 (r
2
 =0.99). The result is illustrated 
in Figure 4.13. 
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Figure 4. 13  From top to down: Epinephrine Si isocaffeine(0.5mM), Epinephrine Si 
isocaffeine(0.25mM), Epinephrine Si isocaffeine(1mM), Epinephrine Si isocaffeine(0mM), 
Epinephrine,Epinephrine Si isocaffeine(2mM)  
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Figure 4. 14  From top to down: Epinephrine MCM caffeine(0mM), Epinephrine MCM 
caffeine(2mM), Epinephrine MCM caffeine(0.25mM), Epinephrine MCM caffeine(0.5mM), 
Epinephrine MCM caffeine(1mM), Epinephrine 
 
Lastly, MCM-41 effect was also carried out in the presence of caffeine. Figure 4.14 shows 
before adding MCM and caffeine, oxidation rate is (7.57 + 0.02)×10
-5
 s
-1
 (r
2
=0.999), After 
addition of caffeine, with the concentration changing from 0.25mM to 2mM, the oxidation rate 
changes to (9.36 + 0.014)×10
-5
 s
-1
 (r
2
 ＞0.99), (7.76 + 0.014)×10-5 s-1 (r2 ＞0.99), (7.47 + 
0.003)×10
-5
 s
-1
 (r
2
 ＞0.99), (7.36 + 0.002)×10-5 s-1 (r2 ＞0.99), (7.44 + 0.006)×10-5 s-1 (r2 ＞0.99). 
4.3  Conclusions and Discussions 
 
 
Influence of mesoporous silica (MCM-41 and SBA-15) nanoparticles and dense silica 
nanoparticles on epinephrine oxidation is pH-dependent. Oxidation rate is small in acidic or 
neutral solutions and will be increased significantly at higher pH. MCM-41 and silica spheres 
does not accelerate the oxidation rate in dH2O while SBA-15 does, indicating that the difference 
in the structures of nanomaterials leads to different effects on the epinephrine oxidative process. 
Comparing to MCM-41 and silica sphere, SBA-15 has a unique microporosity and inter-
connectivity in the mesopore walls, which contributes to a substantial part of total surface area.
37
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This feature could lead to more traps of oxygen radicals inside the mesoporous channel and thus 
significantly accerlate the oxidation of epinephrine even in a weak acidic condition.  In PBS 
solutions, the presence of SBA-15 and MCM-41 makes the oxidation even more rapid. Silica 
spheres have no noticeable influence on the oxidation both in PBS and dH2O. The possibility that 
the catalytic effect of MSN results from the residue of templating chemicals could be excluded 
due to the post-synthesis calcinations. Experiments with dithionite, added either earlier than or at 
the same time as the epinephrine addition, show that fast oxidation takes place only when 
dithionite and epinephrine are simultaneously added into PBS solution.  This confirms a vital 
role of oxygen radicals (probably O2
-
) in the oxidation of epinephrine. These oxygen radicals are 
likely to accumulate within the phosphate buffer or in the presence of mesoporous silica 
nanoparticles. Comparing the three kinds of silica nanoparticles applied, we note that 
mesoporous SBA-15 and MCM-41 materials own much larger surface area than solid silica 
particles do, whereas MCM-41 possesses a much narrower pore size (0.4-fold) than SBA-15. It 
seems, therefore, that large surface area plus characteristic mesoporosity and surface structures 
aid in the deposit of oxygen radicals inside MSN particles, which catalyze the epinephrine 
oxidation in a favorable phosphate environment.  
In the presence of either caffeine or isocaffeine, the oxidation rate of epinephrine by MSN 
will be slowed down. Also, with the increase of caffeine or isocaffeine concentration, the 
oxidation rate decrease accordingly. 
4.4 Experimental section 
4.4.1 Materials and Methods 
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Tetraethylorthosilicate (TEOS), cetyltrimethylammonium bromide (CTAB), and poly 
(ethylene oxide)-block-poly (butylene oxide)-block-poly (ethylene oxide) (P123, EO20PO70EO20) 
were purchased from Sigma-Aldrich. Sodium dithionite (m.w. 174.11) was purchased from Fluka, 
UK. Caffeine (m.w. 194.2), isocaffeine (1, 3, 9-Trimethylxanthine, m.w. 194.2) were ordered 
from Sigma-Aldrich, and dissolved in dH2O or PBS immediately before use. Epinephrine was 
purchased from Sigma-Aldrich (St.Louis, MO). Working solutions (1.0 M) were freshly made in 
dH2O under argon shield. Phosphate-buffered salt solution (1x PBS, without Mg
2+
 and Ca
2+
, pH= 
7.4) was purchased from Mediatech (Herndon, VA).  
4.4.2 Synthesis of Silica Nanoparticles 
 SBA-15 was synthesized as reported by using P123 in acidic solution as a template.
38,39
 
Usually, a solution of EO20PO70EO20 : 2 M HCl : tetraethoxysilane (TEOS) : H2O = 2 : 60 : 4.25 : 
15 (mass ratio) was stirred at 40 °C for 20 h, and then aged at 80 °C for another 24 h in the oven. 
The solution was then filtered, and the solid was washed with a large amount of water and dried 
to get “as-synthesized” SBA-15. The synthesis of MCM-41 was obtained by following a 
previously reported method with minor modification.
40,41
 4.0 g (1.1 mmol) CTAB was dissolved 
in 960 mL Millipore water and then added 14 mL 2.0 M NaOH solution. The mixed solution was 
moderately stirred at 80 °C for half hour and then 22.6 mL (101.2 mmol) TEOS was added. 
After stirring for another 2 h at 80 °C, the solution was filtered and the precipitate was washed 
four times with Millipore water, each time 80 mL, followed by rinsing with ethanol four times, 
each time 80 mL and dried in the oven at 80 °C.  
Silica microspheres were synthesized by following the well-known Stöber method. 5.84 g of 
TEOS was added to 10 mL of 5 M ammonia solution (30 wt %) in a mixture of 50 ml ethanol 
and 3.6 g Millipore water under stirring to allow the hydrolysis of TEOS. After stirring for 12 h, 
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a colloidal solution of silica spheres was obtained. The solution was centrifuged at 6500 rpm for 
five minutes and the supernatant was dumped. The precipitate was then re-dispersed in a mixture 
of 20 mL Millipore water and 20 mL ethanol. The centrifugation and re-dispersing process was 
repeated several times to remove any unreacted chemicals. The resulting silica microspheres 
were dried before further modification.  
4.4.2  Preparation of PBS solutions containing silica nanoparticles, caffeine, isocaffeine, or 
epinephrine 
 
Oxidation rates of epinephrine in various PBS solutions were measured in the experiments 
and the absorbance of adrenochrome (one of oxidized products of epinephrine) at 480 nm versus 
time was plotted, followed by fitting the data into linear functions and obtaining the slope. More 
specifically, 10 mg/mL SBA-15 or silica spheres were individually dispersed in 2×PBS (freshly 
diluted from 10× PBS stock) and sonicated until well suspended. Each suspension was then 
centrifuged, and 1 ml supernatant was taken to mix with 1 ml 250 M freshly prepared 
epinephrine solution that contained caffeine or isocaffeine in different concentrations (e.g., 0.5, 
1.0, 2.0 and 4 mM). The mixtures were instantly collected for the spectroscopic scans. That is, 
finally the mixture contained 125 M epinephrine, final concentrations of caffeine or isocaffeine 
(e.g., 0.25, 0.5, 1.0, and 2.0mM) and 1×PBS, plus certain amount of nanomaterial residues. Our 
previous studies on drug adsorption by silica nanoparticles showed that centrifugations were not 
sufficient to remove all nanoparticles from the supernatant. 
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CHAPTER 5 pH CONTROLLABLE DRUG RLEASE STUDY USING PAA 
ENCAPSULATED MESOPOROUS SILICA MATRIX 
 
5.1 introduction 
 
In order to better control drug release process and drug administration, controlled delivery 
systems has become the research field of interest of many scientists recently. Nowadays, many 
organic delivery systems like polymeric nanoparticles, micelles and liposomes have been 
investigated for delivery system. However, one of the disadvantages of these organic delivery 
carriers is their poor stability due to biochemical attack. More and more interest of scientists has 
focused on mesoporous silica materials to use as carriers in controlled drug release for their 
stability, nontoxic nature, adjustable pore size, high internal and external surface area
1
 and more 
importantly, plenty of Si-OH bonds on the surface which can be further functionalized with 
various groups. 
To achieve controlled release purpose, usually the mesoporous materials are functionalized 
with stimuli-responsive materials, typically polymers. Most common stimuli are pH 
2-9
, 
temperature 
10-12
, redox potential
13
, electric field 
14, 15
, light 
16-18
, magnetic field 
19
, enzyme
21
, salt 
concentration
22
 and etc. Upon a little change in surroundings, stimuli-responsive materials can 
show dramatic and different responses: conformational or shape change, solubility, degradation, 
swelling or collapsing, change of hydrophilicity or hydrophobicity and etc.  Through these 
stimuli response, the drug release loaded in the materials can be controlled as expected. However, 
to achieve controlled release in medicine, stimuli-responsive delivery systems have to show their 
response properties within the setting of biological conditions. Now that different organs, tissues 
and cellular compartments may have large differences in pH, for example, tumor and 
inflammatory tissues (pH 6.8), endosomes (pH~5.5-6), and lysosomes (pH ~ 4.5-5.0), stomach 
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(pH ~1.0-3.0) and intestine (pH ~5-8), so a release strategy that employs pH as a stimulus for 
drug release would be particularly useful. In this study, pH responsive release study was 
conducted.  Ibuprofen and R6G were used as model drug molecules. For the ibuprofen loading, 
amine functionalized MCM (NH2-MCM) was chosen as carrier because -NH2 group is helpful 
for the adsorption of ibuprofen, while amine and thiol bi-functionalized MCM (NH2-MCM-SH) 
was chosen as carrier for the adsorption R6G because –SH is suitable for R6G loading according 
our previous study.
22
 Poly(acrylic acid) PAA was encapsulated onto the silica matrix as pH 
stimuli because it is a well-known bioadhesive hydrogel and often used in drug formulation. 
5.2 Result and discussion 
5.2.1 Release study via UV-Vis test 
 
The UV-Vis absorption spectra were measured with a Lambda-950 spectrophotometer 
(PerkinElmer). Calculated from the UV-Vis absorption spectra data, amount of R6G loaded into 
NH2-MCM-SH sample is 0.0327mmol/g, while the amount loaded to NH2-MCM-SH after PAA 
encapsulation is 0.0321 mmol/g. There is no obvious change in the loading amount of R6G, 
which indicates that the R6G release during encapsulation step of the PAA can be neglected. 
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Figure 5. 1 Release amount (mmol/g) of R6G from various functionalized mesoporous samples. 
(a) NH2-MCM-SH at pH 1.0 (b) NH2-MCM-PAA at pH 1.0 (c) NH2-MCM-SH at pH 7.4 (d) 
NH2-MCM- PAA at pH 7.4 
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For all the samples, the release rate of R6G was fast in the initial first hour and then slowed 
down. Table 5.1 shows after 30.5 h hour, release amount of R6G reached the maxmum of 
0.00525 mmol/mg at pH 1.0 which is more than the release amount (0.00227 mmol/mg) at pH 
7.4. The increase in rate and amount released can be attributed to decreased electrostatic 
interactions between the positively charged rhodamine 6G molecules and the surface of silica at 
the different pH conditions.  It is known that the surface of mesoporous silica is negatively 
charged above isoelectric point (pH 2-3). At pH 1.0, the surface of silica is positively charged 
and it is negatively charged at pH 7.4. Also, amine groups on the silica surface were protonated 
to a greater extent at pH 1.0 than at pH 7.4, which also contribute to the positive charge on the 
silica surface at pH .10. So, at PH 1.0, surface of silica has more positive charge which will 
repulse cationic rhodamine 6G molecules and thus contribute the larger release amount. 
For NH2-MCM-PAA sample, besides the above discussed electric interaction between drug 
molecules and silica surface or protonated amine groups, the dissociation of PAA become 
another factor needed to be considered for the R6G release. The reason is that PAA is a weak 
polyelectrolyte with repeated pendant carboxylic groups with a pKa of 4.5-5 and its shape mainly 
depends on the pH of the surroundings. At pH 1.0 (pH pka 4.5), the side carboxylic groups 
cannot be dissociated and remains contracted and block the openings of the materials and thus 
retard the escaping of R6G molecules while at pH 7.4 (pH pka 5), the side carboxylic groups 
can be dissociated and negative charge on the PAA will repulse each other and dissolve in the 
release media, so, opening of the samples will make the R6G molecules release easier. The 
release result will depend on which factor dominates the process. If electric interaction dominate 
the release process, there will be more release amount at pH 1.0 than at pH 7.4 as for sample 
without PAA encapsulation while if PAA dominate the process, there will be less release at pH 
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1.0 because PAA remains contracted and block the openings of mesoporous matrix. Table 5.1 
shows that after 30.5 h, the release amount is 0.00356 mmol/mg at pH 1.0, which is more than 
the release amount (0.00117 mmol/mg) at pH 7.4. It indicates that electric interaction still 
dominates the release process instead of PAA encapsulation. 
Table 5. 1 R6G release (mmol/g) at pH 1.0 and pH 7.4 over the time 
time/h 
Different conditions 
pH 1.0 
pH 1.0 PAA 
pH 7.4 
pH 7.4 PAA 
1 0.00466 0.00296 0.00140 0.000870 
3 0.00472 0.00305 0.00152 0.000803 
6 0.00511 0.00354 0.00190 0.00100 
9 0.00520 0.00349 0.00200 0.00110 
20 0.00520 0.00363 0.00222 0.00122 
30.5 0.00525 0.00356 0.00227 0.00117 
51.7 0.00472 0.00348 0.00214 0.00100 
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Figure 5. 2 Release of ibuprofen from various functionalized mesoporous samples (A) NH2-
MCM at pH 7.4  (B) NH2-MCM-PAA at pH 7.4 (C) NH2-MCM at pH 1.0 and (D) NH2-MCM-
PAA at pH 1.0  
 
For all the samples, the release rate of ibuprofen was fast in the initial first hour and then 
slowed down. For NH2-MCM sample, Table 5.2 shows after 9 hour, release amount of ibuprofen 
reached the maxmum of 94.4 mg/g at pH 1.0 which is less than the release amount (302.6 mg/g) 
at pH 7.4. For NH2-MCM -PAA sample, ibuprofen release amount of ibuprofen at pH 1.0 is 85.3 
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mg/g which is also less than the 304.1 mg/g release amount at pH 7.4. Release amount at pH 1.0 
is less than that at pH 7.4 for both samples (with or without PAA encapsulation), which is 
different from the above discussed R6G release result. 
This result can also be explained from the electric interaction between ibuprofen molecules and 
silica surface, protonated amine group and dissociation of PAA. For NH2-MCM sample, on one 
hand there is positive charge on silica surface at pH 1.0 and negative charge at pH 7.4. On the 
other hand, ibuprofen molecules have negative charge after dissociation at pH 7.4 (pH pka 5) 
while not at pH 1.0 (pH pka=4.5) because ibuprofen cannot be dissociated. So there is repulsion 
between ibuprofen and silica surface and thus more release at pH 7.4. For NH2-MCM-PAA 
sample, on one hand, electric interaction factor favors the releasing of ibuprofen. On the other 
hand, PAA was dissociated at pH 7.4 which also favors the ibuprofen releasing.  
Lastly, drug (R6G or ibuprofen) release amount from PAA covered samples is less than the 
corresponding samples without PAA cover at the same pH condition( pH 1.0 or pH 7.4).  It is 
easy to understand that PAA acts as a barrier when the drug molecules release from the 
mesoporous matrix and thus reduce the release amount. 
 
Table 5. 2 Ibuprofen release (mg/g) at pH 1.0 and pH 7.4 over the time (h) 
time/h Different conditions 
pH 1.0  
pH 1.0 PAA 
pH 7.4 
pH 7.4 PAA 
1 75.8 64.1 298.0 161.9 
3 67.2 68.4 304.1 285.9 
6.25 89.7 80.6 307.1 281.4 
9 94.4 85.3 302.6 304.1 
23.5 90.3 79.4 275.3 249.6 
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5.2.2 TGA data of different samples 
 
The thermogravimetric (TGA) traces were collected by using a Q-500 Quantachrome 
Analyzer (TA-Instruments) with N2 (99.999 %) as a carrier gas with a heating ramp of 5 ºC/min. 
The TGA traces of samples (Figure 5.3-Figure 5.6) show a weight loss below 100 C due to 
physisorbed water and a weight loss at ~200-600 C due to the loss of organic functional groups. 
 
Figure 5. 3 Weight loss of R6G loaded NH2-MCM-SH (A) after release at pH 7.4, (B) before 
release and (C) after release at pH 1.0.  
 
 
 
 
 
Figure 5. 4  Weight loss of R6G loaded NH2-MCM-SH-PAA (A) before release (B) after release 
at pH 1.0 and (C) after release at pH 1.0 
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Table 5.3 shows the weight loss data of ibuprofen loaded samples before and after release at 
different pH condition from TGA test. The total release amount of ibuprofen can be calculated 
from the difference of the TGA data before and after release.  
For NH2-MCM sample, Table 5.3 shows that release amount of ibuprofen at pH 7.4 is 12.1% 
which is larger than the release amount of 3.0% at pH 1.0. For NH2-MCM -PAA sample, 
ibuprofen release amount of ibuprofen at pH 7.4 is 7.0% which is also larger than the 0.1% 
release amount at pH 1.0. For NH2-MCM-PAA sample, it is noted that there are 0.1% ibuprofen 
release at pH 1.0 comparing 7.00 % release at pH 7.4. The TGA result is consistent with the Uv-
vis data we discussed above. 
 
 
Figure 5. 5 Weight loss of ibuprofen loaded NH2-MCM (A) after release at pH 7.4, (B) after 
release at pH 1.0 and (C) before release. 
 
 
 
Figure 5. 6 Weight loss of ibuprofen loaded NH2-MCM-PAA (A) after release at pH 7.4, (B) 
after release at pH 1.0 and (C) before release 
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Table 5. 3 Weight loss of Ibuprofen loaded samples at pH 1.0 and pH 7.4 
Sample  Before release 
(%) 
After release 
(%) 
Release amount 
(%) 
NH2-MCM pH 1.0 23.29 
 
20.29 
 
3.00 
pH 7.4 23.29 
 
11.17 
 
12.1 
NH2-MCM-PAA pH 1.0 23.14 
 
23.24 
 
0.1 
pH 7.4 23.14 
 
16.15 
 
7.00 
 
5.3 Experiment section 
5.3.1  Synthesis of Organoamine functionalized MCM-41 
 
Mesoporous materials, MCM-41 was synthesized as reported previously.
23
 
5.3.2 Loading and release   
 
 
To load R6G into mesoporous matrix, 30 mg NH2-MCM-SH was mixed with 10 mL 1mM 
solution of R6G. The suspension was vortexed and then kept undisturbed for 48 h. Then, the 
solution was centrifuged and the R6G supernatant was taken out by pipette. The remaining silica 
particles were dried in the oven overnight for the release study.  For ibuprofen loading, 30mg 
NH2-MCM was mixed with 3 mL 20 mg/mL solution of ibuprofen/hexane solution for 48h and 
then, centrifuge the suspension and take ibuprofen supernatant out of the stock solution.  
To get PAA encapsulation mesoporous matrix, 10ml 3mg/mL solution of PAA (Fw=1800) 
was added to the above R6G or ibuprofen loaded samples and keep for 10 min. Then centrifuge 
the solution and take out the PAA supernatant. Lastly, dry all the samples for 48h before release 
test. The resulted samples were denoted as NH2-MCM-PAA and NH2-MCM-SH-PAA, 
respectively. For the release study, 30 mL solution (HCl/KCl buffer) of pH 1.0 or pH 7.4 ×1 PBS 
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solution was mixed with the above R6G or ibuprofen loaded samples. Then the solution was 
stirred consistently at 37°C. Take 1mL solution at different time interval and centrifuge for 
30min before UV-Vis test. Take the upper supernatant for test. Last, add 1mL fresh same release 
solution back to the release system. 
5.4 Conclusion 
 
For R6G release study, NH2-MCM-SH was used and it is concluded that there are more 
release amount at pH 1.0 than at pH 7.4 for sample with or without PAA encapsulation. For 
ibuprofen release study, NH2-MCM was used and there is less ibuprofen release at pH 1.0 than at 
pH 7.4 for sample for both with and without PAA encapsulation. On one hand, electric 
interaction factor favors the releasing of ibuprofen. On the other hand, PAA was dissociated at 
pH 7.4 which also favors the ibuprofen releasing. Lastly, drug (R6G or ibuprofen) release 
amount from PAA covered samples is less than the corresponding samples without PAA cover at 
the same pH condition ( pH 1.0 or pH 7.4).   
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CHAPTER 6 CONCLUSIONS 
 
    The lower efficiency of traditional ways of delivering drugs, like oral administration and 
injection, to humans for some therapies makes new delivery systems necessary. A class of 
mesoporous silicates materials such as MCM-41 and SBA-15 has attracted the attention of many 
scientists as drug delivery vehicles for their high surface area, high porosity, well-ordered, 
tunable nanometer pores and “non-cytotoxic” properties. Because MCM-41 and SBA-15 are 
promising candidates of drug delivery vehicles, in this dissertation, comparative investigation of 
the adsorption capacity and drug release properties of MCM-41 and SBA-15 was conducted. The 
surfaces of the materials were functionalized with judiciously chosen organic groups via post-
grafting or co-condensation of various organosilanes and two different hydrophobic and 
hydrophilic molecules, i.e., ibuprofen and R6G, were used as model drugs in the study. Finally, 
oxidation of epinephrine in the presence of the two MSN, SBA-15 and MCM-41, as well as 
silica microspheres was also investigated. Antioxidant effects of caffeine and its metabolites 
were also evaluated by the epinephrine oxidation rate. The same experiments were also 
performed with its isomer, isocaffeine. Based on the findings of this study, the following 
conclusions could be drawn: 
    The adsorption capacity and release properties of MCM-41 for different drug molecules 
can be controlled by functionalizing them with judiciously chosen organic groups. Some 
functional groups can increase adsorption capacity while some groups can decrease adsorption 
capacity.  
 Functional groups have different effects on adsorption and release capacity for different drug 
molecules. Groups that can increase adsorption of R6G may decrease adsorption of ibuprofen. 
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   When SBA-15 was functionalized with mercaptopropyl and carboxylic acid, it was found 
that R6G adsorption capacity increased and ibuprofen adsorption decreased after 
functionalization. Mercaptopropyl and carboxylic acid affected adsorption to different extents.  
Samples with larger adsorption amounts did not necessarily have larger release amounts or larger 
release percentages than samples with smaller adsorption amounts. 
     For both R6G and ibuprofen, release amount, release percentage of total amounts loaded 
in the sample and release rate from COOH-SBA are larger than that from COOH-MCM sample.   
     MCM-41 and silica spheres do not accelerate the epinephrine oxidation rate in dH2O 
while SBA-15 does. In PBS solutions, the presence of SBA-15 and MCM-41 makes the 
oxidation even more rapid than in dH2O. The effect of MCM-41 and SBA-15 nanoparticles and 
dense silica nanoparticles on epinephrine oxidation is pH-dependent.  
     Silica spheres have no noticeable influence on epinephrine oxidation in PBS and dH2O. It 
seems, therefore, that large surface area plus characteristic mesoporosity and surface structures 
aid in the deposit of oxygen radicals inside MSN particles, and thus deposited oxygen radicals 
help to catalyze the epinephrine oxidation in a favorable phosphate environment.  
    In the presence of either caffeine or isocaffeine, the oxidation rate of epinephrine by MSN 
is slowed down. Also, with the increase of caffeine or isocaffeine concentration, the oxidation 
rate decreases. 
    As a candidate for pH-responsive release, PAA works well for ibuprofen release study, but 
works only slightly for R6G release study.  
 6.1 Limitation and recommendation for future study 
 
For the drug adsorption and release studies of MCM-41 and SBA-15 described in this 
dissertation, only two drug molecules were used and all the conclusions were based on these 
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results. For these drugs, adsorption capacity and release rates can be tuned by organic 
functionalization.  Probably, the method of tuning adsorption and release properties by organic 
functionalization of mesoporous materials could be extended to other organic functional groups 
and to a variety of other drug molecules. Such additional studies should be performed to further 
confirm our findings. 
 In addition, introducing secondary bioactive groups or ligands onto the surfaces of the 
materials may allow targeted delivery of the drug cargo to specific cells, such as cancer cells. 
The mesoporous silica can be loaded with drug cargo and then targeting ligand can be 
conjugated to the surface of the mesoporous silica. Selective targeting strategies employ ligands 
that specifically interact with receptors expressed on the cell surface of interest to promote 
nanocarrier binding and internalization.  
   Another extension of the procedures we have investigated could be the functionalization of 
the mesoporous materials’ internal and external pores with two groups of different 
hydrophobicity, followed by loading two different drug molecules.  Drug combination is most 
widely used in treating the most dreadful diseases, such as cancer and AIDS. The main aims are 
to achieve synergistic therapeutic effect, dose and toxicity reduction, and to minimize or delay 
the induction of drug resistance.  
    Drug delivery study focus on the adsorption and release property by changing physical 
interaction, such hydrogen bonding, hydrophilic and hydrophobic interaction, or electronic  
interaction between durg molecules and mesoporous materials.There are no chemical interaction 
between drug molecules and mesoporous materials in the studies in this thesis. Actuually, 
Epinephrine oxidation studies is a separate project, but from this study, we also can get some 
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information about the possible chemical reaction between drug molecules and mesoporous 
materials in future study. 
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